

CV

1. **Name Surname** : Engin Ulukaya
2. **Date of Birth** : 24.01.1965
3. **Title** : Professor
4. **State of Education** : MD, PhD
5. **Current Institution** : Istinye UNİVERSİTY

Degree	Department	UNİVERSİTY	Date
Bachelor's Degree	Faculty of Medicine	Istanbul University	1981-1988
Expertise in medicine	Department of Biochemistry	Uludağ University	1992-1995
PhD	Department of Biochemistry and Molecular Biology	University of Leeds	1996-2000

5. Academic Appointments

- Assistant Professor (Date) : 2000-2003
Associate Professor (Date) : 2003-2009
Professor (Date) : 2009-

6. Theses Advised

6.1. Postgraduate Theses

Hiperlipidemik Olgularda A Vitamini ve (Beta-Karoten Düzeyleri ile çeşitli plazma lipidleri arasındaki ilişkilerin incelenmesi (U. U. Bursa Faculty of Medicine, Department of Biochemistry, Bursa, TURKEY)

Supervisor: Prof. H Asuman TOKULLUGIL

6.2. Doctoral Theses

Effects of Fenretinide on Squamous Cell Carcinoma Cells and Fibroblasts in Skin (University of Leeds, Department of Biochemistry and Molecular Biology, Leeds, UK)

Supervisor: Prof. Edward J WOOD

7. Publications

7.1. Articles published in internationally refereed journals (SCI,SSCI,Arts and Humanities)

1- **Ulukaya E** and Güler A H. General Practitioners' Opinions about the Basic Sciences in Relation to Medicine. Biochemical Education, 23(3):143, 1995

2- Kaya H, Delibaş N, Serteser M, **Ulukaya E** and Özkaya O. The Effect of Melatonin on Lipid Peroxidation During Radiotherapy in Female Rats. Strahlentherapie und Onkologie, 175:285-288, 1999

3- **Ulukaya E** and E J Wood. Fenretinide and Its Relation to Cancer. Cancer Treatment Reviews, 25:229-235, 1999

4- **Ulukaya E**, Kurt A and Wood E J. 4-(N-Hydroxyphenyl)retinamide can Selectively Induces Apoptosis in Human Epidermoid Carcinoma Cells but not in Normal Dermal Fibroblasts. Cancer Investigation 19(2): 1-12, 2001

5- **Ulukaya E**, Pirianov G, Kurt M A, Wood E J and Mehmet H. Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation. Cell Death Differ 10:856-859, 2003

6- **Ulukaya E**, Colakogullari M and Wood E J. Interference by anti-cancer chemotherapeutic agents in the MTT - tumor chemosensitivity assay. Chemotherapy 50:43-50, 2004

- 7- Demiray M, Gülten M, Manavoğlu O, Evrensel T, **Ulukaya E**, Yerci O, Kanat O, Arslan M, Kurt E, Gonullu G, Demiray H, Gulden T, Memik F. Evaluation of the effects of helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective, sixth-month follow-up study. *Hepatogastroenterology*. 51(59):1531-5, 2004
- 8- Karasu Z, Ulukaya S, Ayanoglu HO, Basturk B, **Ulukaya E**, Akyildiz M, Tokat Y. Cytokine Gene Polymorphism and Early Graft Rejection in Liver Transplant Recipients. *Transplant Proc*. 36(9):2791-5, 2004
- 9- Kaya H, Ozkaya O, Sezik M, Arslanoglu E, Yilmaztepe A, **Ulukaya E**. Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women. *Maturitas*. 14;50(3):182-8, 2005
- 10- Yilmaztepe A, **Ulukaya E**, Ersoy C, Yılmaz M and Tokullugil AH. Investigation of Fecal Pancreatic Elastase-1 Levels in Type 2 Diabetic Patients. *Turkish Journal of Gastroenterology*. 16(2):75-80, 2005
- 11- Demiray M, **Ulukaya E**, Arslan M et al... Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study. *Cancer Invest*. 24(7):669-76, 2006.
- 12- Colakogullari M, **Ulukaya E**, Yilmaztepe A, Januaryoglu G, Yilmaz M, Karadag M, Tokullugil A. Higher Serum Nitrate Levels Are Associated With Poor Survival in Lung Cancer Patients. *Clinical Biochemistry* 39:898-903, 2006.
- 13- **Ulukaya E**, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The Levels of Caspase-cleaved Cytokeratin 18 are Elevated in Serum from Patients with Lung Cancer and Helpful to Predict the Survival. *Lung Cancer*. 56:399-404, 2007
- 14- Yilmaz Y, Dolar E, **Ulukaya E**, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. *World J Gastroenterol*. 13:837-844, 2007
- 15- Yilmaztepe A, **Ulukaya E**, Zik B, et al... Soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is Decreased in Lung Cancer Patients Showing Progression: A Pilot Study. *Cancer Invest*. 25(5):322-7, 2007
- 16- Colakogullari M, **Ulukaya E**, Oral AY, et al. The involvement of IL-10, IL-6, IFN- γ , TNF- α and TGF- β Gene Polymorphisms in Lung Cancer among Turkish Population. *Cell Biochem Funct*. 26(3):283-90, 2008
- 17- Kaya H, Desdicioglu R, Sezik M, **Ulukaya E**, et al. Does sphingosine-1-phosphate have a protective effect on cyclophosphamide- and irradiation-induced ovarian damage in the rat model? *Fertil Steril*. 89(3):732-5, 2008
- 18- Dasdag S, Akdag Z, **Ulukaya E**, et al. Mobile phone exposure does not induce apoptosis on spermatogenesis in rats. *Arch Med Res*. 39(1):40-4, 2008
- 19- **Ulukaya E**, Ozdikicioglu F, Yilmaztepe A et al. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. *Toxicol In Vitro*. 22(1):232-9, 2008
- 20- Akkaya O, Kiyici M, Yilmaz Y, **Ulukaya E**, Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. *World J Gastroenterol*. 13:5481-5485, 2007
- 21- Ozdikicioglu F, **Ulukaya E**, Yilmaztepe AO. The Differential Anticancer Effects of Green Tea in Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cell Lines. *Adv Mol Med*. 3:69-75, 2007
- 22- Yilmaztepe OA, **Ulukaya E**, Yilmaz Y. VEGF, VEGF-receptors and lung cancer. *Adv Mol Med*. 3:15-21, 2007
- 23- Ulukaya S, Basturk B, Kilic M, **Ulukaya E**. Cytokine gene polymorphism and postreperfusion syndrome during orthotopic liver transplantation. *Transplant Proc* 40: 1290-1293, 2008
- 24- Yilmaz Y, **Ulukaya E**, Dolar E. "A biomarker biopsy" for the diagnosis of NASH: promises from CK-18 fragments. *Obes Surg*. 2008 Nov;18(11):1507-8
- 25- Yilmaz Y, **Ulukaya E**, Dolar E. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. *Hepatology*, 49(2):697, 2009

- 26-** Yilmaz Y, Dolar E, **Ulukaya E**. Commentary on the study of Vos et al. "Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr.* 49(3):371, 2009
- 27-** Yilmaz Y, **Ulukaya E**, Dolar E. The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond. *Hepatology*, 49(3):1056-7, 2009
- 28-** Yilmaz Y, **Ulukaya E**, Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S, Dolar E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease.. *Clin Biochem.* 42(9):802-7, 2009.
- 29-** Yilmaz Y, Dolar E, **Ulukaya E**, Akgoz S, Keskin M, Kiyici M, Yerci O, Oral AY, Gul CB, Gurel S, Nak SG, Gulden M. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. *Med Sci Monit.* 15(4):CR189-93, 2009
- 30-** Yilmaz Y, **Ulukaya E**, Atug O, Dolar E. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. *Eur J Gastroenterol Hepatol.* 21(11):1247-51, 2009.
- 31-** Senturk T, Aydinlar A, Yilmaz Y, Yilmaztepe Oral A, Ozdabakoglu O, **Ulukaya E**. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. *Coron Artery Dis.* 20(8):494-8, 2009.
- 32-** Dasdag S, Akdag MZ, **Ulukaya E**, Uzunlar AK, January AR. Effect of mobile phone exposure on apoptotic glial cells and status of oxidative stress in rat brain. *Electromagn Biol Med.* 2009;28(4):342-54.
- 33-** Taskin E, Akgün-Dar K, Kapucu A, Osanc E, Dogruman H, Eraltan H, **Ulukaya E**. Apoptosis-Inducing Effects of *Morinda citrifolia L.* (Noni) and Doxorubicin on the Ehrlich Ascites (EAC) Tumor in Balb-c Mice. *Cell Biochemistry and Function* 27:542-546, 2009
- 34-** **Ulukaya E**, Yilmaz Y, Moshkovskii S, Vlaslova M, Pyatnitskiy M, Ozlen A, Dolar E. Proteomic analysis of serum in patients with nonalcoholic steatohepatitis using MALDI-TOF/MS. *Scandinavian Journal of Gastroenterology.* 44:1471-6, 2009
- 35-** Gul OO, Tuncel E, Yilmaz Y, **Ulukaya E**, Gul CB, Kiyici S, Yilmaztepe Oral A, Guclu M, Ersoy C, Imamoglu S. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetic patients. *Metabolism-Clinical and Experimental.* 59: 64-69, 2010
- 36-** Linder S, Olofsson MH, Herrmann R, **Ulukaya E**. Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. *Expert Rev Mol Diagn.* 10: 353-359, 2010
- 37-** **Ulukaya E**, Acilan C, Yilmaz M, Yilmaztepe-Oral A, Ari F, Zik B, Ursavas A, Tokullugil AH. sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients. *Cell Biochem Funct.* 28: 565-570,2010
- 38-** Ulukaya S, **Ulukaya E**, Alper I, Yilmaztepe-Oral A, Kilic M. Soluble Cytokeratin-18 Biomarkers May Provide Information of the Type of Cell Death During Early Ischemia and Reperfusion Periods of Liver Transplantation. *Clin Transplant.* 24: 848-854, 2010
- 39-** Akdag MZ, Dasdag S, **Ulukaya E**, Uzunlar AK, Kurt MA, Taşkın A. Effects of Extremely Low-Frequency Magnetic Field on Caspase Activities and Oxidative Stress Values in Rat Brain. *Biol Trace Elem Res.* 138: 238-249, 2010
- 40-** Ari F, İkitimur EI, **Ulukaya E**. The ATP assay, but not the MTT assay, detects further cytotoxicity of the combination of anthracycline-based therapy with histone deacetylase inhibitor (Valproic acid) in breast cancer cells. *Turk J Biochem.* 35: 293-299, 2010
- 41-** Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY, Celikel CA, Korkmaz S, **Ulukaya E**, Ozdogan O, Imeryuz N, Avsar E, Kalayci C. Serum fetuin A/alpha 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. *Annals of Clinical Biochemistry.* 47: 549-553, 2010
- 42-** Yilmaz Y, **Ulukaya E**. Molecular signatures of nonalcoholic fatty liver disease:The present and future. *Hepatology.* 51:1866-1866, 2010
- 43-** Yilmaz Y, Yonal O, Kurt R, Oral AY, Eren F, Ozdogan O, Ari F, Celikel CA, Korkmaz S, **Ulukaya E**, Imeryuz N, Kalayci C, Avsar E. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. *Scandinavian Journal Of Clinical & Laboratory Investigation.* 70: 541-546, 2010

- 44-** E. Guney, V.T. Yilmaz, F. Ari, O. Buyukgungor, **E. Ulukaya**. Synthesis, characterization, structures and cytotoxic activity of palladium(II) and platinum(II) complexes containing bis(2-pyridylmethyl)amine and saccharinate. *Polyhedron*.30(1) 114-112, 2011 **SCI**
- 45-** Yilmaz Y, Yonal O, Kurt R, Alandab YO, Ozdogan O, Celikel CA, **Ulukaya E**, Imeryuz N, Kalayci C, Avsar E. Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease. *Archives of Medical Research* 42:38-43, 2011 **SCI**
- 46- Ulukaya E**, Yagci A, Zik B, Sevimli A, Yilmaztepe OA, Akgoz S, Bayer S, Ursavas A. The Expressions of pAkt and PTEN in Lung Cancer Patients 24 Hours After the Cisplatin-Based Chemotherapy: A Prospective Pilot Study. *UHOD*. 21:26-33, 2011 **SCI-Expanded**
- 47- Ulukaya E**, Karaagac E, Ari F, Oral AY, Adim SB, Tokullugil AH, Evrensel T. Chemotherapy Increases Caspase-Cleaved Cytokeratin 18 in the Serum of Breast Cancer Patients. *Radiology and Oncology* 45: 116-122, 2011 **SCI-Expanded**
- 48- Ulukaya E**, Acilan C, Yilmaz Y. Apoptosis: Why and how does it occur in biology? *Cell Biochem Func* 29: 468-480, 2011 **SCI**
- 49-** Ari F, Napieralski R, **Ulukaya E**, Dere E, Colling C, Honert K, Krüger A, Kiechle M, Schmitt M.. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine. *Cell Biochem Funct. Cell Biochem Funct.* 29(8):651-9, 2011 **SCI**
- 50- Ulukaya E**. Acilan C, Ari F, İkitimur E, Yilmaz Y. A glance at the methods for detection of apoptosis qualitatively and quantitatively. *Turk J Biochem* 36:261-269, 2011 **SCI-Expanded**
- 51- Ulukaya E**, Ari F, Dimas K, Sarimahmut M, Guney E, Sakellaridis N, Yilmaz VT. Cell death-inducing effect of novel palladium(II) and platinum(II) complexes on non-small cell lung cancer cells in vitro. *J Cancer Res Clin Oncol.* 137(10):1425-34, 2011. **SCI**
- 52- Ulukaya E**, Ari F, Dimas K, İkitimur EI, Guney E, Yilmaz VT. Anti-cancer activity of a novel palladium(II) complex on human breast cancer cells in vitro and in vivo. *Eur J Med Chem.* 46(10):4957-63, 2011 **SCI**
- 53-** Yilmaz Y and **Ulukaya E**. Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis. *Current Medicinal Chemistry.* 18:725-732, 2011 **SCI**
- 54-** Maria Grazia Daidone, et al. Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. *EJC Supp* 9, no. 2: 120–127, 2012 **SCI**
- 55-** Yerlikaya A, Okur E, **Ulukaya E**.The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomid. *Tumour Biol.* 2012 Apr 4. [Epub ahead of print]. PMID:22477712 **SCI**
- 56-** Ferda ARI, Serap CELIKLER, Seyhan ORAN, Necmiye BALIKCI, Sule OZTURK, Mustafa Z Ozel, Dilek Ozyurt, **Engin ULUKAYA**. Genotoxic, Cytotoxic and Apoptotic Effects of Hypogymnia physodes (L.) Nyl. on Breast Cancer Cells. *Environ Toxicol.* 7: 804-813, 2014 **SCI**
- 57-** Ari F, Sarimahmut M, **Ulukaya E**. Peripherally located A431 cells are more sensitive to cell death induced by exogenous oxidative stress. *Current Signal Transduction Therapy.* 7: 202-208, 2012 **SCI-Expanded**
- 58-** Bozcuk H, Abali H, Coskun S, Lung Cancer Committee of Turkish Oncology Group.The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. *World J Surg Oncol.* 2012 Aug 9;10(1):161. doi: 10.1186/1477-7819-10-161. **SCI-expanded**
- 59-** Tsimplouli C, Pantazis P, Alevizopoulos K, **Ulukaya E**, Dimas K. Patient-Derived Xenografts: Real-Time Modeling of Cancer, Leon V. Berhardt (Ed), *Advances in Medicine and Biology*, Volume 57, Nova Science Publishers, NY, USA, 2012. **BOOK CHAPTER**
- 60-** Saliha Sahin, Ferda Ari, Cevdet Demir, **Engin Ulukaya**. Isolation of major phenolic compounds, antioxidant and cytotoxic activities of extracts from *Prunella L.* species grown in Turkey. *Journal of Food Biochemistry.* 38: 248-257, 2014. **SCI**

- 61-** Iysel C, Yilmaz VT, Ari F, **Ulukaya E**, Harrison WT. trans-Dichloridopalladium(II) and platinum(II) complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine: Synthesis, structural characterization, DNA binding and in vitro cytotoxicity studies. *Eur J Med Chem.* 2013 Feb;60:386-94. doi: 10.1016/j.ejmech. **SCI**
- 62-** Ari F, Napieralski R, **Ulukaya E**. Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell Lines. *Turk J Biochem (Accepted)* **SCI-EXP**
- 63-** Ceyda Iysel, Veysel T. Yilmaz, Aysegul Golcu, **Engin Ulukaya**, Orhan Buyukgungor. Synthesis, crystal structures, DNA binding and cytotoxicity of two novel platinum(II) complexes containing 2-(hydroxymethyl)pyridine and pyridine-2-carboxylate ligands. *Bioorg Med Chem Lett.* 2013 Feb 8. doi:pii: S0960-894X(13)00152-2. 10.1016/j.bmcl **SCI**
- 64-** Cevatemre B, Ari F, Sarimahmut M, Yilmaztepe AO, Dere E, Kacar O, Adiguzel Z, Acilan C, **Ulukaya E**. Combination of fenretinide and indole-3-carbinol results in synergistic cytotoxic activity inducing apoptosis against human breast cancer cells in vitro. *Anticancer Drugs.* 24: 577-586, 2013 **SCI**
- 65-** Ari F, **Ulukaya E**, Sarimahmut M, Yilmaz VT. Palladium(II) saccharinate complexes with bis(2-pyridylmethyl)amine induce cell death by apoptosis in human breast cancer cells in vitro. *Bioorg & Med Chem.* 21: 3016-3021, 2013 **SCI**
- 66-** **Ulukaya E**, Frame F, et al. Differential Cytotoxic Activity of a Novel Palladium-Based Compound on Prostate Cell Lines, Primary Prostate Epithelial Cells and Prostate Stem Cells. *PLOS ONE.* 8: 1-13, 2013 **SCI-exp**
- 67-** Coskun MD, Ari F, Oral AY, Sarimahmut M, Kutlu HM, Yilmaz VT, **Ulukaya E**. Promising anti-growth effects of Palladium(II) complex saccharinate complex of terpyridine by inducing apoptosis on transformed fibroblasts in vitro. *Bioorg & Med Chem.* 21: 4698-4705, 2013 **SCI**
- 68-** Mehmet Zulkuf Akdag , Suleyman Dasdag , Ali Kemal Uzunlar, **Engin Ulukaya** , Arzu Yilmaztepe Oral, Necla Çelik , Feyzan Akşen. Can safe and long-term exposure to extremely low frequency (50 Hz) magnetic fields affect apoptosis, reproduction, and oxidative stress. *Int J Radiat Biol.* 89(12):1053-60, 2013 **SCI**
- 69-** Ari F, Aztopal N, Iysel C, Yilmaz VT, Guney E, **Ulukaya E**. Synthesis, structural characterization and cell death-inducing effect of novel palladium(II) and platinum(II) saccharinate complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine on cancer cells in vitro. *Bioorg Med Chem.* 21(21):6427-34, 2013 **SCI**
- 70-** Ari F, Aztopal N, Oran S, Bozdemir S, Celikler S, Ozturk S, **Ulukaya E**. *Parmelia sulcata* Taylor and *Usnea filipendula* Stirt. Induce Apoptosis-Like Cell Death and DNA Damage in Cancer Cells. *Cell Proliferation.* 47: 457-464, 2014. **SCI**
- 71-** Ari F, Cevatemre B, İkitimur EI, Aztopal N, Yilmaz VT, **Ulukaya E**. Apoptosis-Inducing Effect of a Palladium (II) Saccharinate Complex of Terpyridine on Human Breast Cancer Cells in vitro and in vivo. *Bioorg Med Chem.* 22: 4948-4954, 2014 **SCI**
- 72-** Celikler S, Oran S, Ari F, **Ulukaya E**, Aztopal N, Sarimahmut M, Ozturk S. Genotoxic, Cytotoxic, and Apoptotic Effects of Crude Extract of *Usnea filipendula* Stirt. in vitro. *Turk J Biol.* 38: 940-947, 2014 **SCI-exp**
- 73-** Adiguzel Z, Baykal AT, Kacar O, Yilmaz VT, **Ulukaya E**, ACILAN C. The biochemical and proteomic analysis of a potential anticancer agent: Palladium(II) Saccharinate Complex of Terpyridine acting through double strand break formation. *Journal of Proteome Research.* 13:5240-5249,2014 **SCI-exp**
- 74-** Kacar O, Adiguzel Z, Yilmaz VT, Cetin Y, Cevatemre B, Arda N, Baykal AT, **Ulukaya E**, Acilan C. Evaluation of the molecular mechanisms of a palladium(II) saccharinate complex with terpyridine as an anticancer agent. *Anticancer Drugs.* 2014 Jan;25(1):17-29 **SCI**
- 75-** **Ulukaya E**, Sarimahmut M, Cevatemre B, Ari F, Yerlikaya A, Dimas K. Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro. *Biomedicine & Pharmacotherapy* 68: 477-482, 2014 **SCI**
- 76-** Karakas D, Cevatemre B, **Ulukaya E**. Cancer stem cells: Emerging actors in basic and clinical cancer research. *Turkish J Biology.*38: 829-838, 2014 **SCI-exp**
- 77-** Bicer M, Senturk T, Yanar M, Tutuncu A, Oral AY, **Ulukaya E**, Serdar Z, Signak IS. Effects of off-pump versus on-pump coronary artery bypass grafting: apoptosis,

inflammation, and oxidative stress. *Heart Surg Forum*. 2014 Oct 1;17(5):E271-6. doi: 10.1532/HSF98.2014326. PubMed

78- Azmi Yerlikaya, Emrah Okur, Ahmet Tarık Baykal, Ceyda Acılan, İhsan Boyacı, **Engin Ulukaya**. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. *Journal of Proteomics* 113:315-325, 2015 **SCI**

79- Azmi Yerlikaya, Emrah Okur, Ahmet Tarık Baykal, Ceyda Acılan, İhsan Boyacı, **Engin Ulukaya**. Data for a proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line. *Data in Brief*. DOI: 10.1016/j.dib.2014.09.003 Open Access

80- Elif Ilkay Ikitimur-Armutak, Kivilcim Sonmez, Kadriye Akgun-Dar, Gulbin Sennazli, Aysegul Kapucu, Funda Yigit, Veysel Turan Yilmaz, **Engin Ulukaya**. Anti-Cancer Effect of a Novel Palladium-Saccharinate Complex of Terpyridine by Inducing Apoptosis on Ehrlich Ascites Carcinoma (EAC) in Balb-C Mice. *Anticancer Res*. 35:1491-7, 2015. **SCI**

81- Antunovic M, Kriznik B, **Ulukaya E**, Yilmaz VT, Mihalic KC, Madunic J, Marijanovic I. Cytotoxic Activity of Novel Palladium-Based Compounds on Leukemia Cell Lines. *Anti-cancer drugs*. 26: 180-186, 2015 **SCI**

82- Özlem Sağlam, Zehra Seda Ünal, Cansu Subaşı, **Engin Ulukaya**, Erdal Karaöz . IL-6 originated from Breast Cancer Tissue-Derived Mesenchymal Stromal Cells May Contribute to Carcinogenesis. *Tumour Biol*. 36:5667-77, 2015 **SCI**

83- Cevatemre B, **Ulukaya E**, Sarimahmut M, Oral YA, Frame FM. The M30 Assay does not detect apoptosis in epithelial-derived cancer cells expressing low levels of cytokeratin 18. *Tumour Biol*. 36:6857-65, 2015. **SCI**

84- Muhammet Altunok, Ferhat Can Özkaya, Semih Engin, Tevfik Tansel Tanrikul, Şeyma Aydınlık, **Engin Ulukaya**. In vitro antibacterial activity of sponge-associated fungi against bacterial aquaculture pathogens. *Fresenius Environmental Bulletin* Vol. 24; 2158-2166, 2015. **SCI-Exp**

85- Oral AY, Cevatemre B, Sarimahmut M, Iysel C, Yilmaz VT, **Ulukaya E**. Anti-Growth Effect of a Novel trans-Dichloridobis[2-(2-hydroxyethyl)pyridine]platinum(II) Complex via Induction of Apoptosis on Breast Cancer Cell Lines. *Bioorg Med Chem*. 23:4303-10, 2015 **SCI**

86- Dimas K., **Ulukaya E.**, Sakellaridis N. , Cancer of the Eye (Intraocular Cancer), Reference Module in Biomedical Sciences. Elsevier. 12-Jun-2015 doi: 10.1016/B978-0-12-801238-3.99473-X

87- Dimas K., **Ulukaya E.**, Sakellaridis N. , Salivary Gland Tumors, Reference Module in Biomedical Sciences. Elsevier. 12-Jun-2015 doi: 10.1016/B978-0-12-801238-3.99478-9

88- Ceyda Iysel, Veysel T. Yilmaz, Yunus Kaya, Selvi Durmus, Mehmet Sarimahmut, **Engin Ulukaya**, Orhan Buyukgungor. Cationic Pd(II)/Pt(II) 5,5-diethylbarbiturate complexes with bis(2-pyridylmethyl)amine and terpyridine: Synthesis, structures, DNA/BSA interactions, intracellular distribution, cytotoxic activity and induction of apoptosis. *J Inorg Biochem*. 152:38-52. 2015. **SCI**

89- Nahide Gulsah Deniz, Cemil Ibis, Zeliha Gokmen, Maryna Stasevych, Volodymyr Novikov, Olena Komarovska-Porokhnyavets, Mustafa Ozyurek, Kubilay Guclu, Didem Karakas, **Engin Ulukaya**. Design, Synthesis, Biological Evaluation, Antioxidant and Cytotoxic Activity of Heteroatom Substituted 1,4-Naphtho- and Benzoquinones. *Chem. Pharm. Bull*. 63, 1029–1039 (2015) **SCI**

90- Karakas D, Cevatemre B, Aztopal N, Ari F, Yilmaz VT, **Ulukaya E**. Addition of niclosamide to palladium(II) saccharinate complex of terpyridine results in enhanced cytotoxic activity inducing apoptosis on cancer stem cells of breast cancer. *Bioorganic and Medicinal Chemistry*. 23:5580-5586, 2015 **SCI**

2016

91- Mehmet Sarimahmut, Necmiye Balikci, Serap Celikler, Ferda Ari, **Engin Ulukaya**, Gurcan Guleryuz, Mustafa Zafer Ozel. Evaluation of Genotoxic and Apoptotic Potential of *Hypericum adenotrichum* Spach. in vitro. *Regulatory Toxicology and Pharmacology* 74:137-146, 2016 **SCI-Exp**

92- Aztopal N, Erkisa M, Celikler S, **Ulukaya E**, Ari F. Anti-growth and apoptosis inducing effects of *Hypericum olympicum* L. and *Hypericum adenotrichum* Spach. on lung

cancer cells in vitro: Involvement of DNA damage. *Journal of Food Biochemistry*. 40:559-566, 2016 **SCI**

93- Aztopal N, Cevatemre B, Sarimahmut M, Ari F, Dere E, Ozel MZ, Firat M, **Ulukaya E**. Pelargonium quercetorum Agnew induces apoptosis without PARP and cytokeratin 18 cleavage in non-small cell lung cancer cell lines. *Oncology Letters* 12: 1429-1437, 2016 **SCI-Exp**

94- Yilmaz V, **Ulukaya E**, et al. Ni(II)/Cu(II)/Zn(II) 5,5-diethylbarbiturate complexes with 1,10-phenanthroline and 2,2'-dipyridylamine: Synthesis, structures, DNA/BSA binding, nuclease activity, molecular docking, cellular uptake, cytotoxicity and the mode of cell death. *Dalton Transactions* 45:10466-10479, 2016

95- Korkmaz S, Sarimahmut M, Ozel MO, **Ulukaya E**. Olive leaf extract containing oleuropein modulates the cytotoxic effect of epirubicin on breast cancer cells depending on the cell line. *Turk J Biochem* 41: 385-392, 2016. **SCI-Exp**

96- Cevatemre B, Botta B, Mori M, Berardozi S, Ingallina C, **Ulukaya E**. The plant-derived triterpenoid tingenin B is a potent anticancer agent due to its cytotoxic activity on cancer stem cells of breast cancer in vitro. *Chemico-Biological Interactions* 260: 248-255, 2016 **SCI**

97- Ikitimur Armutak EI, **Ulukaya E**, et al. Apoptosis-inducing Effect of a Palladium(II) Complex-[PdCl(terpy)](sac)center dot 2H₂O] on Ehrlich Ascites Carcinoma (EAC) in Mice. *In vivo* 30:457-464,2016

98- Acilan C, Cevatemre B, Adiguzel Z, Karakas D, **Ulukaya E**, Ribeiro N, Correia I, Pessoa JC. Validation data supporting the characterization of novel copper complexes as anticancer agents. *Data in Brief* 9:1160-1174, 2016

99- Erdemoglu N, Ayaz F, **Ulukaya E**, Sarimahmut M. Cytotoxic effect of *Conyza canadensis* (L.) Cronquist on human lung cancer cell lines. (Accepted by *Turkish Journal of Pharmaceutical Sciences*)

100- Ebru GUREL-GUREVIN; H. Tuba KIYAN; Seyma AYDINLIK; Veysel Turan YILMAZ; Konstantinos DIMAS; **Engin ULUKAYA**. Anti-Angiogenic Effect of a Palladium(II)-Saccharinate Complex of Terpyridine in vitro and in vivo (Accepted by *Microvascular Research*). **SCI**

2017

101- Kacar O, Cevatemre B, Hatipoglu I, Arda N, **Ulukaya E**, Yilmaz VT, Acilan C. The role of cell cycle progression for the apoptosis of cancer cells induced by palladium(II)-saccharinate complexes of terpyridine. *Bioorg Med Chem* 25:1770-1777, 2017.

102- Ferda Ari, Nazlihan Aztopal, Merve Erkisa, Serap Celikler, Saliha Sahin, **Engin Ulukaya**. Nonapoptotic cell death induced by *Hypericum* species on cancer cells. *Eur Res J* 3(1):1-10. 2017

103- Kacar O, Cevatemre B, Hatipoglu I, Arda N, **Ulukaya E**, Yilmaz VT, Acilan C. The role of cell cycle progression for the apoptosis of cancer cells induced by palladium(II)-saccharinate complexes of terpyridine. *Bioorg Med Chem* 25:1770-1777, 2017

104- Tunc D, Dere E, Karakas D, Cevatemre B, Yilmaz VT, **Ulukaya E**. Cytotoxic and apoptotic effects of the combination of palladium (II) 5,5-diethylbarbiturate complex with bis(2-pyridylmethyl)amine and curcumin on non small lung cancer cell lines. *Bioorg Med Chem* 25:1717-1723, 2017

105- Aydinlik S, Erkisa M, Cevatemre B, Sarimahmut M, Dere E, Ari F, **Ulukaya E**. Enhanced cytotoxic activity of doxorubicin through the inhibition of autophagy in triple negative breast cancer cell line. *Biochim Biophys Acta* 1861:49-57, 2017

106- Aztopal N, Karakas D, Cevatemre B, Ari F, Icel C, Daidone MG, **Ulukaya E**. A trans-platinum(II) complex induces apoptosis in cancer stem cells of breast cancer. *Bioorg Med Chem*. 25:269-276, 2017

107- Ikitimur-Armutak EI, Gurel-Gurevin E, Kiyani HT, Aydinlik S, Yilmaz VT, Dimas K, **Ulukaya E**. Anti-angiogenic effect of a Palladium(II)-Saccharinate Complex of Terpyridine in vitro and in vivo. *Microvasc Res*.109:26-33, 2017

108- Acilan C, Cevatemre B, Adiguzel Z, Karakas D, **Ulukaya E**, Ribeiro N, Correia I, Pessoa JC. Synthesis, biological characterization and evaluation of molecular mechanisms of novel copper complexes as anticancer agents. *Biochim Biophys Acta*. 1861:218-234, 2017

109- Oral AY, Oral HB, Sarimahmut M, Cevatemre B, Ozkaya G, Korkmaz S, **Ulukaya E**. Combination of esomeprazole with chemotherapeutics results in more pronounced cytotoxic effect via apoptosis on A549 nonsmall-cell lung cancer cell line. *Turk J Biochem* 41: 231-241, 2017.

110- Coskun D, Erkisa M, **Ulukaya E**, Coskun MF, Ari F. Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: Synthesis, characterization and anticancer activity. *Eur J Med Chem* 136: 212-222, 2017

111- M. Stasevych , V. Zvarych , V. Lunin, N. G. Deniz, Z. Gokmen, O. Akgun, **E. Ulukaya**, V. Poroikov , T. Glorizova and V. Novikova. Computer-aided prediction and cytotoxicity evaluation of dithiocarbamates of 9,10-anthracenedione as new anticancer agents. SAR and QSAR in Environmental Research. <http://dx.doi.org/10.1080/1062936X.2017.1323796>. 2017

112- Acilan C..... **Ulukaya E**.... A palladium(II)-saccharinate complex of terpyridine exerts higher anticancer potency and less toxicity than cisplatin in a mouse allograft model (accepted by anticancer drugs)

113- Ferda Ari, Serap Çelikler, Didem Karakaş, Buse Cevatemre, Mehmet Fırat, **Engin Ulukaya**. Total Phenolic Content, Antioxidant and Cyto-/Genotoxic Activities of *Pelargonium quercetorum* Agnew in Human Breast Cancer Cells (accepted by Journal of Clinical and Experimental Investigations)

114- V. T. Yilmaz, C. Iysel, F. Suyunova, M. Aygun, B. Cevatemre and **E. Ulukaya**. Synthesis, structures, DNA/protein binding, molecular docking, anticancer activity and ROS generation of Ni(II), Cu(II) and Zn(II) 5,5-diethylbarbiturate complexes with bis(2-pyridylmethyl)amine and terpyridine (Accepted by New Journal of Chemistry)

115- DumanFD, Erkisa M, Khodadust, Ari F **Ulukaya E**, Acar HY. Folic Acid-Conjugated Cationic Ag₂S Quantum Dots For Optical Imaging and Selective Doxorubicin Delivery to HeLa Cells. (Accepted by Nanomedicine).

116- Cevatemre B, **Ulukaya E**. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autophagy in breast cancer. (Accepted by pharmacological research).

117- Nazlıhan Aztopal, Merve Erkisa, Elif Ertürk, Asuman Tokullugil, **Engin Ulukaya**, Ferda Ari. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells. (Accepted by Chemico-Biological Interactions).

2018

118- Önder Aybastıer, Sam Dawbaa, Cevdet Demir, Oğuzhan Akgün, **Engin Ulukaya**, Ferda Ari. Quantification of DNA damage products by gas chromatography tandem mass spectrometry in lung cell lines and prevention effect of thyme antioxidants on oxidative induced DNA damage. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis*. 808:1-9. 2018

119- Dimas K **Ulukaya E**. Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging precious allies in the war on a devastating cancer. *Journal of Proteomics*. 2018

7.2. Articles published in other internationally refreed journals

7.3. Assertions presented in international scientific congresses and published in the proceedings

1-Ulukaya E. Tumor chemosensitivity and chemoresistance assays. 24th World Associations of Societies for Pathology and Laboratory Medicine (WASPALM) Meeting. 20-24 August 2007. Kuala Lumpur, Malaysia. (Invited speaker)

2- Ulukaya E. 3. Tumor Chemosensitivity Assay and Its Applications in Oncology Practice. Ulusal Onkoloji Kongresi. 14-15 September 2007. Samarkand, Uzbekistan (Invited speaker)

3- Ulukaya E. A promising role of caspase-cleaved cytokeratin 18 (M30 antigen) in oncological research. The 12th World Congress of Advances in Oncology. 11-13 October 2007, Crete, Greece (Invited speaker)

4-Ulukaya E. Chemotherapy-induced cell death and its assessment in vivo. 5th Conference on Experimental and Translational Oncology. 26-30 March 2008, Kranjska Gora, Slovenia (Invited speaker)

5-Ulukaya E. Apoptosis and its relation to cancer. XVI. National Congress of Biochemistry and The Second International Biosciences Days. 23-27 October 2000, Selçuk (Invited speaker)

6-Ulukaya E. The relationship between apoptosis and cancer. 2nd Congress of Molecular Medicine. 24-26 March 2007, Istanbul (Invited speaker)

7-Ulukaya E, Stockwin H, Mehmet H and Wood E J. Fenretinide can Induce Cytochrome c Release from Mitochondria into the Cytosol in Squamous Cell Carcinoma Cells. *The American Society for Biochemistry and Molecular Biology Meeting. Graduate/Postdoctoral Travel Award Program.* 4 June 2000, Boston, USA

8-Ulukaya E, Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT- tumor chemosensitivity assay. *The 22nd World Congress of Pathology and Laboratory Medicine.* 30 August-3 September, 2003, Busan, KOREA

9-Ulukaya E, Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. *The 2nd ISCO (International Society for Chemosensitivity Testing in Oncology) Symposium.* 15-16 September, 2003, Portsmouth, ENGLAND

10-Ulukaya E, Yilmaz M, Yilmaztepe A, Zik B, Karadag M. Response of lung cancer patients to cisplatin-based anti-cancer treatments: Effects on the levels of cleaved cytokeratin 18 and sFas. *4th European Workshop on Cell Death.* 11-16 May, 2004. Istanbul, TURKEY.

11-Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. M30 antigen levels could be used in the prediction of survival of lung cancer patients. 11th World Congress on Advances in Oncology and 9th International Symposium on Molecular Medicine. 12-14 October, 2006, Crete, Greece.

12-Ulukaya E, Dolar E, Yilmaz Y, et al. Noninvasive serum biomarkers may help to differentiate steatohepatitis from simple steatosis. 17th APASL Conference. 27-30 March 2007, Kyoto, JAPAN.

13-Ulukaya E. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. II. EORTC-PBG Meeting. 27-28 April 2007, Halle. GERMANY. (No abstract but a proof showing the attendance)

14-Ulukaya E and Wood E J. Fenretinide Induces Cell Death by Apoptosis in Epidermoid Carcinoma Cells but not in Human Normal Dermal Fibroblasts. *The First International Biosciences Days and XVth National Congress of Biochemistry.* 20-24 April 1999, Antalya, Turkey

15-Tokullugil H A, Dirican M and **Ulukaya E.** An Investigation into a Food Additive: Sodium Benzoate. *Meeting of the International Federation of Clinical Chemistry (IFCC).* 8 -12 July 1996, London, UK

16-Tokullugil A H, **Ulukaya E,** Dirican M and Tuncel P. Investigation of Plasma Vitamin A Levels in Hyperlipidemia Subjects. *Meeting of the International Federation of Clinical Chemistry (IFCC).* 8 -12 July 1996, London, UK

17-Ulukaya E and Wood E J. 4-Hydroxyphenyl retinamide (4HPR) Selectively Induces Cell Death in Squamous Cell Carcinoma Cells Without Affecting Human Fibroblasts in the Skin Equivalent Systems. *Annual Scientific Meeting of Yorkshire Cancer Research.* 14 December 1998, UNIVERSITY of York, UK

18-Ulukaya E and Wood E J. 4-Hydroxyphenyl retinamide (4HPR) Prevents Migration of Squamous Cell Carcinoma Cells into Dermis. *UK Molecular Biology and Cancer Network Meeting XV.* 14th-16th December 1998, UNIVERSITY of Warwick, UK

19-Ulukaya E and Wood E J. The Apoptosis-Inducing Effect of Fenretinide on Squamous Cell Carcinoma Cells of Vulva. *3rd International Congress on Vitamins and Related Biofactors.* 30 June - 3 July 1998, Goslar, Germany.

20-Ulukaya E and Wood E J. 4-Hydroxyphenyl retinamide-Induced Apoptosis in Squamous Cell Carcinoma Cells of Vulva: Role of Ca²⁺. *669th Meeting of the Biochemical Society.* 20-22 July 1999, UNIVERSITY of Keele, UK

21-Ulukaya E and Wood E J. Confluency Prevents Mild Oxidative Stress-Induced Cell death and F-Actin Damage in Cells Treated with Exogenous H₂O₂. *BSCB/BSDB Joint Spring Meeting*. 13-16 April 1999, Manchester, UK

22-Ulukaya E and Wood E J. Disappearance of Actin Stress Fibres Occurs Before Nuclear Condensation in Oxidative Stress-Induced Cell death of Dermal Fibroblasts. *The Society for Investigative Dermatology*, 60th Annual Meeting. 5-9 May 1999, Chicago, USA

23-Ulukaya E and Wood E J. An in vitro Model for Migration of Squamous Cell Carcinoma (SCC) Cells into Dermis. *The First International Biosciences days and XVth National Congress of Biochemistry*. 20-24 April 1999, Antalya, Turkey

24-Ulukaya E and Wood E J. F-actin is One of the Target Proteins for Fenretinide-Induced Apoptosis in Squamous Cell Carcinoma Cells. *26th Meeting of the Federation of European Biochemical Societies (FEBS'99)*. 19-24 June 1999, Nice, France

25-Ulukaya E, Okana-Mensah B and Wood E J. Mechanism of the Apoptosis-inducing effect of Fenretinide: Cytochrome c Release from Mitochondria into the Cytosol. *671st Meeting of the Biochemical Society*. 11-14 April 2000, UNIVERSITY of Leeds, UK.

26-Ulukaya E, Stockwin H, Mehmet H and Wood E J. Fenretinide can Induce Cytochrome c Release from Mitochondria into the Cytosol in Squamous Cell Carcinoma Cells. *The American Society for Biochemistry and Molecular Biology Meeting*. 4-8 June 2000, Boston, USA

27-Ulukaya E and Wood EJ. Fenretinide-induced cell death in epidermoid carcinoma is augmented by nifedipine. *674th Meeting of the Biochemical Society*. 11-13 July 2001, Dublin, UK.

28-Ulukaya E and Colakogullari M. Interferences of the MTT Assay, a method for tumor chemosensitivity testing, with some chemicals and anticancer drugs. *17th Meeting of European Association for Cancer Research (EACR)*. 7-11 June 2002, Granada, Spain.

29-Ulukaya E, Yilmaztepe A, Zik B, Yilmaz M, Karadag M. Cleaved cytokeratin 18 (M30) is increased in serum after treating lung cancer patients with cisplatin-based anti-cancer regimens. *18th Meeting of European Association For Cancer Research (EACR)*. 3-6 July, 2004, Innsbruck, Austria.

30-Yagci A, Zik B, Sevimli A, Yilmaztepe A, Yilmaz M, Karadag, M, **Ulukaya E**. Expression status of Akt and Pten in lung cancer patients before and after cisplatin-based anti-cancer treatment. *18th Meeting of European Association For Cancer Research (EACR)*. 3-6 July, 2004, Innsbruck, Austria.

31-Çolakoğulları M, **Ulukaya E**, Yilmaztepe A, Januaryoğlu G, Yılmaz M, Karadağ M, Tokullugil A. Effects of serum nitrite/nitrate and VEGF-A levels on survival of lung cancer patients. *31. FEBS Congress: Molecules in Health and Disease*. 24-29 June 2006. Istanbul, Turkey.

32-Ulukaya E, Yilmaztepe A, Zik B, A Yagci, Erdogan BB, Koc M, Akgoz S, Karadag M, Tokullugil A. Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: a pilot study. 11th World Congress on Advances in Oncology and 9th International Symposium on Molecular Medicine. 12-14 October, 2006, Crete, Greece.

33-Yilmaz Y, Dolar E, **Ulukaya E**, et al. Apoptonecrotic biomarkers in the prediction of liver fibrosis in non-alcoholic fatty liver disease. 17th APASL Conference. 27-30 March 2007, Kyoto, JAPAN.

34-Yilmaz Y, Dolar E, **Ulukaya E**, et al. The relationship between M30 antigen levels and fibrosis in patients with chronic hepatitis C. 17th APASL Conference. 27-30 March 2007, Kyoto, JAPAN.

35-Colakogullari M, **Ulukaya E**, Yilmaztepe AO, Aymak F, Basturk B, Ursavas A, Oral HB. The involvement of IL-10, IL-6, IL-gamma, IL-alfa and TGF-beta gene polymorphisms among Turkish lung cancer patients. Yeditepe UNIVERSITY Hospital Gene Therapy Symposium. 2-3 Nov 2007, Istanbul, Turkey

36- Ulukaya E. Utilization of cytokeratin-based novel biomarkers (M30 and M65) in cancer. V. EORTC PathoBiology Group Annual Meeting. 9-11 Sept 2010, Marseille, France (**Invited speaker**)

37- Ulukaya E. Novel serum biomarkers (M30 and M65) in the better management of cancer patients. HDIR-1: From Bench to Clinic. 11 November 2010. Zagreb, Croatia. (**Invited speaker**)

38- Ulukaya E. Advanced practical course in mammalian cell biology. May 25-June 4 2009, Gebze, İzmit.

39- Omer Kacar, Yuksel Cetin, Engin Ulukaya, Veysel Yilmaz, Ceyda Acilan. Evaluation of Cell Death Mechanisms of Palladium(II) Complex as an Anticancer Agent in Human Cancer Cell Lines. 8. Uluslararası Katılımlı Türk Toksikoloji Derneği Kongresi. (Poster) 15-18 November 2012 Beldibi-Kemer / Antalya

40- Ulukaya E. Sarimahmut M, Cevatemre B, Aztopal N, Coskun MD, Ari F. Investigation of the Apoptotic/Cytotoxic Effects of Combination of TRAIL with Fenretinide in Breast Cancer Cell Lines. 1st Serbian Association of Cancer Research Meeting. 28-30 November 2012, Belgrade . (Poster)

41- Ulukaya E. Palladium-based anticancer agents (and Differential Cytotoxic Activity of a Novel Palladium-Based Compound on Prostate Cell Lines, Primary Prostate Epithelial Cells and Prostate Stem Cells). 1st International BAU-Drug Design Symposium. 21-23 March 2013, İstanbul, TURKEY (Invited speaker)

42- Ulukaya E, Frame FM, Cevatemre B, et al. Differential Cytotoxic Activity of a Novel Palladium-Based Compound on Prostate Cell Lines, Primary Prostate Epithelial Cells and Prostate Stem Cells. 1st Working Group Meeting of COST Action CM1106. 21-22 Feb 2013, Porto, Portugal. Poster presentation.

43- Kacar O, Adiguzel Z, Yilmaz VT, Cetin Y, Cevatemre B, Arda N, Ulukaya E, Acilan C. Investigation of the molecular mechanisms of a palladium(II) saccharinate complex with terpyridine as an anticancer agent. 1st International BAU-drug design symposium. 21-23 March 2013, İstanbul, TURKEY

44- Adiguzel Z, Baykal T, Kacar O, Karakas D, Serhatli M, Ulukaya E, Yilmaz VT, Acilan C. A novel Pd(II) based molecule exerts its toxicity through DNA double strand formation: Analysis via biochemical and proteomic methods. 1st International BAU-drug design symposium. 21-23 March 2013, İstanbul, TURKEY

45- Nazlihan Aztopal¹, Didem Karakas¹, Ferda Ari¹, Veysel T. Yilmaz², Engin Ulukaya³. INVESTIGATION of CYTOTOXIC/APOPTOTIC EFFECTS of a NOVEL SYNTHESIZED PLATINUM (II) COMPLEX [PT(HEPY)₂CL₂] ON HUMAN BREAST CANCER STEM CELLS *in vitro*. EU COST CMST Action CM 1106, Working Groups Meeting. 27-28 March 2014. Budapest, Hungaria

46- Buse Cevatemre, Ferda Ari, Mehmet Sarimahmut, Engin Ulukaya. Detection of apoptosis by M30 assay *in vitro* is not reliable in the cancer cells expressing low level of cytokeratin 18. EACR-Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Mugla.

47- Didem Karakas, Buse Cevatemre, Nazlihan Aztopal, Ferda Ari, Veysel Turan Yilmaz, Engin Ulukaya. An effective novel approach for treatment of breast cancer: combination of Pd (II) complex and niclosamide. **EACR-Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Mugla.**

48- Ferda Ari, Buse Cevatemre, Elif Ilkay Ikitimur, Nazlihan Aztopal, Veysel Turan Yilmaz, Engin Ulukaya. Initial mechanism insights of potential anti cancer agent, Palladium (II) saccharinate complex of terpyridine. **EACR-Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Mugla.**

49- Mehmet Sarimahmut, Buse Cevatemre, Ferda Ari, Azmi Yerlikaya, Konstantinos Dimas, Engin Ulukaya. Additive enhancement of apoptosis by trail and fenretinide in metastatic breast cancer cells *in vitro*. **EACR-Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Mugla.**

50- Elif Ilkay Ikitimur Armutak, Kivilcim Sonmez, Kadriye Akgun Dar, Gulbin Sennazli, Aysegul Kapucu, Funda Yigit,, Engin Ulukaya. The Effect Of Apoptosis and Anti-Cancer Activity of a Novel Palladium (II) Complex on EAC in Balb-C Mice. EACR-

Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Mugla

51- Didem Karakas, Nazlihan Aztopal, Buse Cevatemre, Ferda Ari, Arzu Yilmaztepe Oral, Veysel Turan Yilmaz, **Engin Ulukaya**. Breast cancer stem cells are more resistant than parental cells to a novel palladium (II)- saccharinate complex of terpyridine. 23rd Congress of EACR (European Association for Cancer Research). 5-8 July 2014, Munich.

52- Buse Cevatemre, Ferda Ari, Mehmet Sarimahmut, Arzu Yilmaztepe Oral, **Engin Ulukaya**. M30 assay may not be an accurate method for apoptosis in the cancer cells expressing low level of cytokeratin. 23rd Biennial Congress of the European Association for Cancer Research. 5-8 July 2014, Munich.

53- Mehmet Sarimahmut, Serap Celikler, Ferda Ari, Seyhan Oran, Nazlihan Aztopal, Sule Ozturk, Engin Ulukaya. Apoptosis-inducing effect of *Usnea filipendula* Stirt. in breast cancer cells *in vitro*. 23rd Biennial Congress of the European Association for Cancer Research. 5-8 July 2014, Munich.

54- Ulukaya E. Oxidative stress and cell death in cancer. V. International congress of cell membranes and oxidative stress. 9-12 September 2014, Isparta. (**Invited Speaker**)

55- Ulukaya E. A Promising Novel Palladium-Saccharinate Complex of Terpyridine Against Cancer Stem Cells. 9th International conference of anticancer research. 6-10 October 2014, Sithonia, Greece. (Oral Presentation)

56- Ulukaya E. A Novel Promising Anti-Cancer Compound Against Cancer: A Palladium (II)-Saccharinate Complex of Terpyridine. 3rd HDIR Meeting "From Bench to Clinic". 6-7 Nov 2014. Zagreb, Croatia (**Short talk**)

57- Ulukaya E, Karakaş D, Ari F, Aztopal N, Ayhan CA, Yilmaz VT. Palladium (II)-saccharinate complex of terpyridine seems to be a promising novel compound for the treatment of lung cancer *in vitro*. 19th Congress of the Asian Pasific Society of Respirology. 13-16 Nov 2014. Bali, Indonesia (**Oral presentation**)

58- Arzu Yilmaztepe Oral, Buse Cevatemre, Mehmet Sarimahmut , Veysel T. Yilmaz, **Engin Ulukaya**. Anti-growth effect of novel platinum-hepy complex on breast cancer cell lines. 3rd HDIR Meeting "From Bench to Clinic". 6-7 Nov 2014. Zagreb, Croatia. Poster

59- Buse Cevatemre, **Engin Ulukaya**, Mehmet Sarimahmut, Arzu Yilmaztepe Oral, Didem Karakaş, Nazlihan Aztopal, Fiona M. Frame. M30 assay may not reliably reflect apoptotic cell death in cells expressing low levels of cytokeratin 18. 3rd HDIR Meeting "From Bench to Clinic". 6-7 Nov 2014. Zagreb, Croatia.

60- Didem Karakas , Buse Cevatemre , Nazlihan Aztopal, Ferda Ari, Veysel Turan Yilmaz, **Engin Ulukaya**. An effective novel approach for treatment of breast cancer: combination of Pd(II) complex and niclosamide. 3rd HDIR Meeting "From Bench to Clinic". 6-7 Nov 2014. Zagreb, Croatia.

61- Buse Cevatemre, Didem Karakas, Mehmet Sarimahmut, Seyma Aydinlik, Nazlihan Aztopal, Ceyda Icel, Engin Ulukaya. Possible Cross-talk between Hedgehog, Wnt and Notch Pathways Following a Cytotoxic Treatment with Pd(II)-saccharinate complex of terpyridine. COST Action CM1106 Meeting. 19-20 Jan 2015. Barselona, Spain (Oral presentation).

62- Didem Karakas , Buse Cevatemre , Nazlihan Aztopal, Veysel Turan Yilmaz, **Engin Ulukaya**. Mammospheres (Cancer Stem Cell-Enriched Population) in Breast Cancer Show Resistance Against A Palladium (II)-Saccharinate Complex of Terpyridine. COST CM1106 Working Group Meeting. 26-27 March 2015. Athens, Greece. (Poster)

63- Ulukaya E. Cell death based pharmacodynamic biomarkers for the prediction of response to chemotherapy. International Symposium on Advances in Predictive and Personalized Medicine. 2-3 April 2015. Istanbul (**invited speaker**)

64- Ulukaya E. Cevatemre B, Sarimahmut M, Ari F, Oral AY, Frame FM. M30 assay underestimates apoptosis in the case of inadequate amount of cytokeratin 18 in lung cancer cells. EACR-AACR-SIC congress: Anticancer drug action and drug resistance. 20-23 June 2015. Florence, ITALY (Poster)

65- Ulukaya E, Cevatemre B, Karakas D, Aztopal N, Icel C. Inhibition of sonic hedgehog pathway in breast cancer stem cells does not provide extra benefit in cytotoxicity resulted from Pd(II)-saccharinate complex of terpyridine. MedChem 2015. 5-10 July 2015. Novosibirsk, Russia (**Invited Speaker**)

66- Ulukaya E. Cell death based pharmacodynamic biomarkers (M30 and M65): The pros and cons. 1st International Conference on Natural Products for Cancer Prevention and Therapy. 31 August-2 September 2015. Istanbul, Turkey (**Invited Speaker**)

67- Ulukaya E. Caspase-cleaved cyokeratin 18: How reliable to detect apoptosis? 10th Annual EORTC Pathobiology Group Meeting. 10-12 September 2015. Paris/France (**Invited speaker**)

68- Ulukaya E. Palladium (II) based-anticancer compounds: A new hope or an illusion? 2nd Congress of Serbian Association for Cancer Research. 2-3 October 2015. Belgrade, SERBIA (**Invited speaker**)

69- Buse Cevatemre, Didem Karakaş, Merve Erkisa, Mattia Mori, Simone Berardozzi, Cinzia Ingallina, Bruno Botta and Engin Ulukaya. Dying in Different Ways: Cellular Responses of Breast Cancer Stem Cells and Parental MCF-7 Cells to BB-8. COST action. 5-6 October 2015. Rome, ITALY (Oral presentation)

70- Merve Erkisa, SeymaAydınlık, Buse Cevatemre, Nazlıhan Aztopal, Ferda Ari, Veysel T. Yılmaz, Engin Ulukaya. Autophagy Inhibition with Chloroquine Enhances Cytotoxicity Of Palladium (II)-Barbiturate Complex In Prostate Cancer .2nd Congress of Serbian Association for Cancer Research. 2-3 October 2015. Belgrade, SERBIA (Poster)

71- Şeyma Aydınlık, Merve Erkisa, Buse Cevatemre, Egemen Dere, Engin Ulukaya. Blocking Autophagy Enhanced Cytotoxicity Induced by Doxorubicin In the Metastatic Breast Cancer Cell Line. 2nd Congress of Serbian Association for Cancer Research. 2-3 October 2015. Belgrade, SERBIA (Poster)

72- Duygu Tunc, Didem Karakas, Buse Cevatemre, Pinar Alper, Veysel T. Yılmaz, Engin Ulukaya. Addition of Curcumin to a Palladium (II)-Barbiturate Complex enhances the cytotoxic/apoptotic activity on non small cell lung carcinoma cells. 2nd Congress of Serbian Association for Cancer Research. 2-3 October 2015. Belgrade, SERBIA (Poster)

73- Engin Ulukaya, Seyma Aydinlik, Merve Erkisa, Ferda Ari, Veysel Turan Yılmaz. Palladium (II)-Based Novel Approach to Kill Cancer Stem Cells of Breast Cancer. ESMO Asia 2015. 18-21 December 2015. Singapur (Poster)

74- Ulukaya E. Palladium (II) Based-Anticancer Compounds: A New Hope? 7th International Conference on Drug Discovery and Therapy. 15-18 Feb 2016. Dubai, 2016 (**Invited speaker**)

75- Ulukaya E, Aztopal N, Karakas D, Cevatemre B, Erkisa M, Aydinlik S, Yılmaz VT. Palladium (II)-Saccharinate Complex of Terpyridine Against The Cancer Stem Cells. 4th Workshop of COST Action CM1106. 10-11 March 2016, Chioggia, ITALY (**Oral presentation**)

76- Armutak-Ikitimur E, Gural-Gurevin E, Ulukaya E. Chloroquine enhances the antiangiogenic effect of doxorubicin on the choricallantoic membrane (CAM) in vivo. 24th Biennial Congress of EACR. 9-12 July 2016. Manchester/UK (poster)

77- Ulukaya E, Erkisa M, Aydinlik S, Cevatemre B, Ari F, Yılmaz VT. Targeting breast cancer stem cells by inhibiting Wnt pathway: Combination of Pd(II) complex and niclosamide. 24th Biennial Congress of EACR. 9-12 July 2016. Manchester/UK (poster)

78- O. Kacar, I. Hatipoglu, V. Yılmaz, N. Arda, E. Ulukaya, C.A. Acilan. Elucidation of molecular action mechanisms of cytotoxic palladium derivatives on various cancer cells. 24th Biennial Congress of EACR. 9-12 July 2016. Manchester/UK (poster)

79 C. Acilan, B. Cevatemre, Z. Adiguzel, D. Karakas, E. Ulukaya, N. Arda, N. Ribeiro, I. Correia, J.C. Pessoa. Synthesis, biological characterization and evaluation of molecular mechanisms of novel copper complexes as anticancer agents. 24th Biennial Congress of EACR. 9-12 July 2016. Manchester/UK (poster)

80- Ulukaya E. To test the anticancer activity of any new compound. COST ACTION CM1407. 1st Training School. 24-26 September 2016, Belgrade/Serbia (Lecturer)

81- Merve Erkisa¹, Ferda Ari¹, Seyma Aydınlık¹, Buse Cevatemre¹, Nazlıhan Aztopal¹, Veysel T. Yılmaz², Engin Ulukaya³ AUTOPHAGY INHIBITION ENHANCES PALLADIUM (II)-BARBITURATE COMPLEX -INDUCED APOPTOSIS IN PROSTATE CANCER. 6. Multidisipliner kanser araştırma kongresi. 27-30 October 2016. Konya

82- Nazlıhan Aztopal¹, Didem Karakas¹, Buse Cevatemre¹, Ferda Ari¹, Veysel Turan Yılmaz², Engin Ulukaya³. Inhibition of the WNT Signalling Pathway Sensitizes

Breast Cancer Stem Cells to Pd(II) complex-induced Apoptosis. 6. Multidisipliner kanser arařtırma kongresi. 27-30 October 2016. Konya

83- Oguzhan Akguna, Ferda Ari, Merve Erkısaa, **Engin Ulukaya**. Investigation of the Cytotoxic and Apoptotic Effects of Combination of the Histone Deacetylase Inhibitor and Wnt Pathway inhibitor on Lung Cancer Cell Lines. 6. Multidisipliner kanser arařtırma kongresi. 27-30 October 2016. Konya

84- Serap Celikler¹, Sezin Bozdemir¹, Didem Karakas¹, Ferda Ari¹, Nazlihan Aztopall¹, Veysel Turan Yilmaz², **Engin Ulukaya**³. Genotoxic Activity of Palladium(II) Saccharinate Complex of Terpyridine on Breast Cancer Stem Cells. . 6. Multidisipliner kanser arařtırma kongresi. 27-30 October 2016. Konya

85- Ulukaya E. Deadly Actors in Cancer: Cancer Stem cells. II. International stem cell and regenerative medicine. 19-21 April 2017, Mashhad, IRAN (invited speaker)

86- Merve Erkisa, Gülay Büyükkörođlu, Behiye Senel, Veysel T. Yılmaz, **Engin Ulukaya**, Ferda Ari. Palladium Incorporated Micelle: A Promising Material for Future Non-Small Cell Lung Cancer. 6th International Congress of Molecular Medicine. 22-25 May 2017, Istanbul UNİVERSİTY Congress and Cultural Center.

87- Engin Ulukaya, Pınar Alper, Didem Karakař, Merve Erkisa, Adem Deligönül, Erdem Çubukçu, Sami Bayram, Ferda Ari, Ender Kurt. Reversal of Unresponsive Lung Cancer Cases Treated on the Basis of an Ex Vivo Tumor Chemosensitivity Assay (Onkogram®). 6th International Congress of Molecular Medicine. 22-25 May 2017, Istanbul UNİVERSİTY Congress and Cultural Center.

88- Seyma Aydinlik, Elif I. Ikitimur-Armutak, Ayça Uvez, Ferda Ari, Kıvılcım Sonmez, Osman. B. B. Esener, F. Ustun-Alkan, A. Aktas, S. Umit Zeybek, **Engin Ulukaya**, Konstantinos Dimas, Ebru Gurel-Gurevin. Chloroquine improves the anticancer effects of doxorubicin in vitro and in vivo models on Mouse Mammary Tumor Ehrlich ascites carcinoma (EAC). Making it Personal: Cancer Precision Medicine 13 - 16 March 2017 Amsterdam, Netherlands

89- Engin Ulukaya. Deadly actors: Cancer Stem Cells. Stem cell and regeneratif medicine congress. 19-22 April 2017. Mashaed, Iran (Invited speaker)

90- Engin Ulukaya. Better Treatment Option in Breast Cancer in vitro: Inhibition of Autophagy in Triple Negative Breast Cancer Enhances Cytotoxic Activity of Doxorubicin. 2ng Global insight conference on Breast cancer. 4-6 September 2017. Rome, Italy (Invited speaker, Chair, Member of organising committee)

91- Engin Ulukaya. 12th EORTC pathobiology group annual meeting. Is caspase-cleaved cytokekeratin 18 is not always useful for the prediction of response to chemotherapy? 14-15 september 2017. Aviano, Italy (Invited speaker)

92- Engin Ulukaya. 3D-based methods to evaluate the efficiency of anticancer compounds. 3rd Congress of Serbian Association of Cancer Research. 6-7 October 2017. Belgrade, Serbia (Invited speaker)

93- Engin Ulukaya. Extraordinary Cytotoxic Activity of a Natural Product (Pristimerin) on Breast Cancer In vitro and In vivo. 5th International BAU Drug Design Congress. 19-21 October 2017. Istanbul, Turkey (Invited speaker)

94- Engin Ulukaya. Pristimerin is a promising natural product against breast cancer in vitro and in vivo through apoptosis and the blockage of autophagic flux. 2nd International Conference on Natural Products for Cancer Prevention and Therapy. 8-11 November 2017. Kayseri, Turkey (Invited speaker)

95- Merve Erkisa, Gulay Buyukkorođlu, Behiye Senel, Veysel T. Yılmaz, **Engin Ulukaya**, Ferda Ari. Palladium Incorporated Micelle: A Promising Material for Future Non-Small Cell Lung Cancer. The XV National Congress of Medical Biology and Genetics Congress. 26 – 29 October, 2017. Fethiye, Turkey (Poster presentationu).

96- Cytotoxic Activites of 3-bromo-5-chloro-2-hydroxy-acetophenone-N-phenyl-thiosemicarbazone and 3-bromo-5-chloro-2-hydroxy-acetophenone-N-phenyl-thiosemicarbazidatotriphenylphosphine Nickel(II) Complex Against MCF-7 (Cancer)

Şükriye Güveli, Tülay Bal Demirci, Didem Karakař, **Engin Ulukaya**, Bahri Ülküseven. 3. Uluslararası İlaç ve Eczacılık Kongresi. 26-29 April 2017. İstanbul (poster)

97- N-Substituted Thiosemicarbazones - Synthesis, Characterization and Comparison of Cytotoxicities Against MCF 7 Cell. Şükriye Güveli, Didem Karakaş, **Engin Ulukaya**, Bahri Ülküseven, Tülay Bal Demirci. 3. Uluslararası İlaç ve Eczacılık Kongresi. 26-29 April 2017. İstanbul (poster)

98- The cytotoxic activities of substitue-salicylaldehyde-S-methyl-thiosemicarbazone and it's complex against MCF-7 cell line

99- Şükriye Güveli, Tülay Bal Demirci, Didem Karakaş, **Engin Ulukaya**, Bahri Ülküseven. 3. Uluslararası İlaç ve Eczacılık Kongresi. 26-29 April 2017. İstanbul (poster)

7.4. International books published, or chapters from a book

7.5. Articles published in national refreed journals

1- Güler A H ve **Ulukaya E.** Atomik Absorbsiyon Spektrofotometrisi ve Önemi. *Bursa Devlet Hastanesi Tıp Bülteni* 9(2-3): 113-123, 1993

2- Güler A H ve **Ulukaya E.** Lipoprotein (a)'nın Yapısı ve Plazminojenle Benzerlikleri. *Uludağ Üniv Tıp Fak Derg* 1:109-112, 1993

3- Güler A H ve **Ulukaya E.** Organizmada Eser Element İşlevlerinin Başlıca Özellikleri. *Bursa Devlet Hastanesi Tıp Bülteni* 9(2): 147-157, 1993

4- Güler A H, **Ulukaya E** ve Özkan K. Obesite ile Serum İnsülin ve Lipid Düzeyleri Arasındaki İlişkiler. *Uludağ Üniv Tıp Fak Derg*, 1:31-36, 1994

5- **Ulukaya E**, Tokullugil A H ve Dirican M. Serbest Testosteron ve İnsülin Hormonları ile Trigliserit, Total Kolesterol, HDL-Kolesterol ve Lipoprotein Elektroferezis Fraksiyonları Arasındaki İlişkiler. *Uludağ Üniv Tıp Fak Derg* 1-2-3:47-51, 1995

6- Cangül H, **Ulukaya E** ve Tokullugil HA. Serum total kolesterol ölçümünde Zak ve Flegg yöntemlerinin kıyaslanması. *Çukurova UNİVERSİTY Tıp Fakültesi Dergisi* (22): 273-279, 1997

7- Dirican M, Sarandöl E, **Ulukaya E** ve Tokullugil A H. Yüksek Dansiteli Lipoprotein-Kolesterol Tayininde Dekstran Sülfat-Magnezyum ve Fosfotungstat-Magnezyum Presipitasyon Tekniklerinin İncelenmesi. *Uludağ Üniv Tıp Fak Derg*, 1-2-3:41-45,1998

8- **Ulukaya E**, Dirican M ve Tokullugil A H. Hiperlipidemik ve Normolipidemik Kişilerde Beta-Karoten Düzeyi ile Serum Lipidleri Arasındaki İlişkilerin İncelenmesi. *Uludağ Üniv Tıp Fak Derg*, 125(1-2-3):1-4, 1998

9- **Ulukaya E**, Dirican M ve Tokullugil A H. Investigation of Plasma Vitamin A Levels in Hyperlipidemic Subjects. *Eastern Journal of Medicine* 4(2):61-64, 1999

10- **Ulukaya E.** The Retinoids and Their Relation to Cancer and Apoptosis. *Bursa Tıp Bilimleri Dergisi (Bursa Journal of Medical Sciences)* 4(1-2): 79-82, 2000

11- **Ulukaya E** and Wood E J. The Anti-Proliferative and Cell Death-Inducing Effect of H₂O₂ on Squamous Cell Carcinoma Cells. *Biochemical Society Transactions*, 26:S347, 1998

12. Dirican M, Sarandöl M, **Ulukaya E** and Tokullugil A H. Effects of Smoking on Serum Lipid and Lipoprotein Concentrations and Lecithin:Cholesterol Acyltransferase Activity. *The Journal of Medical Investigation*, 46(3-4):169-172, 1999

13- **Ulukaya E** and Wood EJ. 4-Hidroksifenil Retinamid (4-HPR) in vitro 3-Boyutlu Hücre Kültür Sistemlerinde Skuamoz Hücreli Karsinoma Hücrelerinin Migrasyonunu Önlemektedir. *Bursa Devlet Hast. Bült.* 17(2): 81-84, 2001

14- **Ulukaya E.** Tumor chemosensitivity assay. *Adv Mol Med.* 1(Suppl):327-331, 2005

15- **Ulukaya E.** Drug Response Assay: An Increasing Trend in Designation of Tailored-Chemotherapy for More Rational Management of Cancer Patients. *Adv Mol Med* 2:53-58, 2006

7.6. Assertions presented in national scientific congresses and published in the proceedings.

- 1-**Ulukaya E.** Apoptozisin kanser gelişiminde ve tedavisindeki yeri. *XVII. Ulusal Biyokimya Kongresi.* 24-27 June 2002, Ankara (Invited speaker)
- 2- **Ulukaya E.** Kanser ve apoptozis ilişkisi. I. *Klinik Biyokimya ve Kanser Sempozyumu.* 26-29 September 2002, Bursa
- 3-**Ulukaya E.** İlaç Duyarlılık Testi / Onkogram. I. *Klinik Biyokimya ve Kanser Sempozyumu.* 26-29 September 2002, Bursa
- 4-**Ulukaya E.** Kanser Araştırmada Yenilikler. II. *Klinik Biyokimya ve Kanser Sempozyumu.* 16-18 April2004, Bursa
- 5- **Ulukaya E.** Onkogram. *TURKEY’de Kanser Araştırmalarında Yenilikler Sempozyumu.* 30 June-1May 2004, Eskişehir (Invited speaker)
- 6-**Ulukaya E.** Glial Tümörlerde Biyoloji. 9. *Uludag Onkoloji Sempozyumu.* 16-19 December2004, Bursa (Invited speaker)
- 7-**Ulukaya E.** Sarkomlarda Biyolojik Özellikler. 9. *Uludag Onkoloji Sempozyumu.* 16-19 ralık 2004, Bursa (Invited speaker)
- 8-**Ulukaya E.** Tümör kemosensitivite testi. 1. *Ulusal Moleküler Tıp Kongresi.* 16-19 April2005, İstanbul (Invited speaker)
- 9- **Ulukaya E.** Tümör kemosensitivite testleri. XVI. *Ulusal Kanser Kongresi.* 20-24 April2005, Antalya (Invited speaker)
- 10- **Ulukaya E.** Tümör Kemosensitivite Testleri. 2. *Ulusal Tıbbi Onkoloji Kongresi.* 7-11 September, 2005. Antalya (Invited speaker)
- 11-**Ulukaya E.** Tümör Kemosensitivite Testleri. *Klinik Biyokimya Uzmanlar Derneği 3. Ulusal Kongresi.* 21-24 September 2005, Antalya (Invited speaker)
- 12- **Ulukaya E.** Tümör Kemosensitivite Testleri (Onkogram) ve Kanserdeki Önemi. IX. *Tıbbi Biyoloji Kongresi.* 24-27 November2005, Manisa (Invited speaker)
- 13-**Ulukaya E.** Kanser Araştırmalarında Proteomikinin Önemi. Multidisipliner Kanser Araştırma Sempozyumu. 12-15 March2006, Uludag, Bursa
- 14-**Ulukaya E.** Kaspazla kırılmış sitokeratin 18 (M30 antijen)’in onkolojide ümit verici rolü. X. *Ulusal Tıbbi Biyoloji ve Genetik Kongresi.* 6-9 September 2007, Antalya. (Invited speaker)
- 15-**Ulukaya E.** M30 antijenin kanser tedavisinin etkinliğinin izlenmesinde açtığı yeni ufuklar. II. Multidisipliner Kanser Araştırma Sempozyumu. 24-27 February 2008, Uludag, Bursa.
- 16- **Ulukaya E.** Apoptozisle ilişkili prognostik belirteçler. Programlı Hücre Ölümü Sempozyumu. 9 April2008. İstanbul. (Invited speaker)
- 17- **Ulukaya E.** Tümör Kemosensitivite Testi (Onkogram) ve Jinekolojik Onkolojideki Yeri. 11. *Ulusal Jinekolojik Onkoloji Kongresi.* 30 April-4 May 2008, Antalya. (Invited speaker)
- 18- **Ulukaya E.** Apoptozisin Kliniğe Yansımaları: Kaspazla Kırılmış Sitokeratin 18 (M30 Antijen). *Klinik Biyokimya Uzmanlar Derneği 5. Ulusal Kongresi.* 11-15 January 2009, Uludag. (Invited speaker)
- 19- **Ulukaya E.** Deri kırışıklıklarının tedavisinde otolog uygulamalar ve kök hücre tedavisi. 5. *Ulusal Dermatokozmetoloji Günleri.* 26 February-1 March2009, Bursa (Invited speaker)
- 20-**Ulukaya E,** Wood E J ve Manavoğlu O. Fenretinid vulva kaynaklı skuamöz hücreli kanser hücrelerinde sitokrom c’ nin salıverilmesi yoluyla apoptozisi indükler. *Ulusal Kanser Kongresi.* 30 April-4 May 2001, İstanbul, TURKEY
- 21-**Ulukaya E.** Bir Onkogram yöntemi olan “MTT Viability Assay”in bazı kimyasallarla olan interferansı. 2. *Ulusal Klinik Biyokimya Kongresi.* 31 Ekim-4 Kasım, 2001, Kuşadası, TURKEY
- 22-**Ulukaya E,** Yılmaz M, Yılmaztepe A, Zık B, Karadağ M. Akciğer kanseri hastalarının cisplatin bazlı tedavilere yanıtı: kırılmış sitokeratin 18 ve sFas. II. *Klinik Biyokimya ve Kanser Sempozyumu.* 16-18 April2004, Bursa. (It was presented by Yılmaz).

- 23-Ulukaya E**, Çolakoğulları M. Bir tumor kemosenitivite testi (Onkogram) yöntemi olan “MTT viability assay”in antikanser ajanlarla olan interferansı. *Klinik Biyokimya Uzmanlar Derneği, 2. Ulusal Kongresi*. 21-25 September 2004, Bodrum.
- 24-Yılmaztepe A**, Yılmaz M, Yağcı A, Sevimli A, Zık B, Akgöz S, Karadağ M, Karaağaç E, Tokullugil A, **Ulukaya E**. Akciğer kanseri hastalarında solubl ve VEGF-R1 düzeylerinin incelenmesi. Multidisipliner Kanser Araştırma Sempozyumu. 12-15 March2006, Uludag, Bursa. (It was presented by Yılmaztepe).
- 25-Çolakoğulları M**, Yılmaztepe A, Januaryoğlu G, Yılmaz M, Karadağ M, Tokullugil A, **Ulukaya E**. Akciğer kanseri hastalarında serum VEGF-A ve nitrat-nitrit düzeylerinin sürvi ile olan ilişkisi. Multidisipliner Kanser Araştırma Sempozyumu. 12-15 March2006, Uludag, Bursa. (It was presented by M. Colakogullari).
- 26-Yılmaz Y**, Dolar E, **Ulukaya E**, et al... Üriner albümin ekstreksiyonu steatohepatit için bir tanı belirteci hem de karaciğer fibrozisi için bir prediktif faktör mü? 3. HepatoGastroenteroloji Kongresi. 2-6 September 2006, Antalya. (It was presented by Yusuf Yılmaz).
- 27-Yılmaz Y**, Dolar E, **Ulukaya E**, et al... Apoptonekrotik belirteçlerin non-alkolik yağlı karaciğerli hastalarda (NAFLD) karaciğer fibrozisinin tahmininde tanısal değeri. 3. HepatoGastroenteroloji Kongresi. 2-6 September 2006, Antalya. (It was presented by Yusuf Yılmaz).
- 28-Yılmaz Y**, Dolar E, **Ulukaya E**, et al... Non-alkolik yağlı karaciğerli hastalarda (NAFLD) steatohepatiti basit yağlanmadan ayırmada yeni noninvazif biyomarkır testler. 23. Ulusal Gastroenteroloji Kongresi. 04-07 November2006, İstanbul. (It was presented by Yusuf Yılmaz)
- 29-Akkaya Ö**, Kıyıcı M, Yılmaz Y, **Ulukaya E**, Yerci Ö, Gürel S, Dolar E, Gülten M, Nak SG. Kronik hepatit C virüs enfeksiyonunda normal ALT değeri kaç olmalıdır. 4. Hepato Gastroenteroloji Kongresi. 1-5 September 2007. Antalya
- 30-Yılmaz Y**, Dolar E, **Ulukaya E**, Akgöz S, Keskin M, Kıyıcı M, Yerci Ö, Yılmaztepe Oral A, Gül CB, Gürel S, Nak SG, Gülten M. Nonalkolik steatohepatitli ve kronik hepatit C enfeksiyonlu hastalarda serum kaspaz kırılmış sitokeratin 18 (CK18-Asp396) düzeyleri. 4. Hepato Gastroenteroloji Kongresi. 1-5 September 2007. Antalya
- 31-Ulukaya S**, Alper I, Kılıç A, Yılmaztepe A, **Ulukaya E**. Karaciğer transplantasyonu sırasında oluşan iskemi-reperfüzyon hasarının gösterilmesinde ümit vaat eden yeni serum biobelirteçleri: M30 antijen ve M65 antijen. TARK 2008, 29 ekim-1 November2008, Antalya.
- 32-Dirican M**, Tuncel P, Sarandöl E, **Ulukaya E**, Tokullugil A. Normolipidemik ve hiperlipidemik kişilerde serum lipidleri ve lesitin:kolesterol açıltransferaz aktivitesi. K.T.Ü. Tıp Fakültesi IV. Karadeniz Tıp Günleri, 31 May-3 June 1995-Trabzon.
- 33-Dirican M**, Sarandöl E, Tuncel P, **Ulukaya E**, Tokullugil A. Sigara içen ve içmeyen erkeklerde serum lipid düzeyleri ve lesitin:kolesterol açıltransferaz aktivitesi. K.T.Ü. Tıp Fakültesi IV. Karadeniz Tıp Günleri, 31 May-3 June 1995-Trabzon.
- 34-Ulukaya E**, Tokullugil A, Tuncel P, Dirican M. Hiperlipidemik olgularda A vitamini düzeylerinin incelenmesi. K.T.Ü. Tıp Fakültesi IV. Karadeniz Tıp Günleri, 31 May-3 June 1995, Trabzon.
- 35-Ulukaya E**, Dirican M, Tokullugil A, Tuncel P. Beta-Karoten Potansiyel Bir Aterojenmi? K.T.Ü. Tıp Fakültesi IV. Karadeniz Tıp Günleri, 31 May-3 June 1995-Trabzon.
- 36-Ulukaya E** ve Güler A H. Pratisyen Hekimlerin Mezuniyet Sonrasında Temel Bilimlere Bakışı. *TURKEY'de Tıpta Temel Bilimlerde Eğitim Sempozyumu*. 16-17 April1994, Ankara
- 37-Ulukaya E**, Tokullugil A H ve Dirican M. Serbest Testosteron ve İnsülin Hormonları ile Trigliserit, Total Kolesterol, HDL-Kolesterol ve Lıpoprotein Elektroforezi Fraksiyonları arasındaki İlişkiler. *Türk Fizyolojik Bilimler Derneği 20. Ulusal Kongresi*. 25-29 October 1994, İzmir
- 38-Ulukaya E**. Eksojen olarak oluřturulan oksidatif stresin hücre kültürleri üzerindeki etkisi. 1. *Ulusal Klinik Biyokimya Kongresi*. 19-23 April, 1999, Kuşadası, TURKEY
- 39-Ulukaya E**, Kurt A, Mehmet H ve Wood EJ. Fenretinide induces apoptosis via cytochrome c release without changing mitochondrial transmembrane potential. *XVI. Ulusal*

Biyokimya Kongresi ve İkinci Uluslararası Biyobilim Günleri. 23-27 Ekim, 2000, Selçuk, TURKEY

40-Demiray M, Gülten M, **Ulukaya E**, Evrensel T, Kurt E, Gönüllü G, Kanat Ö, Manavoğlu O. Heliobacter Pylori'nin gastrik epitelyal hücrelerde proliferasyona etkisinin belirlenmesi. *Ulusal Kanser Kongresi.* 30 April-4 May 2001, İstanbul, TURKEY

41-Yağcı A, Zık B, Sevimli A, Yılmaztepe A, Yılmaz M, **Ulukaya E**. Akciğer kanserlerinde dokudaki AKT ve PTEN ekspresyonlarının ve tedaviye yanıtla ilişkilerinin immunohistokimyasal incelenmesi. *II. Klinik Biyokimya ve Kanser Sempozyumu.* 16-18 April2004. Bursa, TURKEY

42-Korkmaz S, Çolakoğulları M, **Ulukaya E**, Öztürk Y. Aspirinin antineoplastik ilaçlarla kombine uygulanmasının küçük hücre dışı akciğer kanseri hücrelerine (A549) etkisinin in vitro incelenmesi. *II. Klinik Biyokimya ve Kanser Sempozyumu.* 16-18 April2004. Bursa, TURKEY

43-Yılmaztepe A, **Ulukaya E**, Ersoy C, Yılmaz M, Tokullugil HA. Diabetik hastalarda fekal elastaz I düzeyleri. *IV. Ulusal Klinik Biyokimya Kongresi.* 5-9 September 2004, Marmaris.

44-Yılmaz M, Dervişoğlu A, Kaya E, Yılmaztepe A, **Ulukaya E**. Akut pankreatitli hastalarda serum pankreatik elastaz-1 düzeyleri. *IV. Ulusal Klinik Biyokimya Kongresi.* 5-9 September 2004, Marmaris.

45-Yağcı A, Zık B, Yılmaztepe A, Sevimli A, Altunbaş K, **Ulukaya E**. Akciğer kanserlerinde cisplatin bazlı kanser tedavisinde akt ve pten'in tedaviye yanıtla ilişkilerinin sürvi analizi. *Multidisipliner Kanser Araştırma Sempozyumu.* 12-15 March2006, Uludag, Bursa

46-Ulukaya E, Yılmaztepe A, Akgöz S, Linder S, Karadağ M. Akciğer kanserinde yeni bir belirteç olarak kaspazla-kırılmış sitokeratin 18 düzeyleri ve tedavi/sürvi ile ilişkisi. *XVII. Ulusal Kanser Kongresi.* 19-23 April 2007, Antalya.

47-Yeğin DA, Yılmaztepe AO, Kale Ş, Arı F, **Ulukaya E**. MDA ve MCF-7 Meme Kanseri Hücre Dizilerinde Kalsiyum Kanal Blokeri olan Verapamilin Dosetaksol, Karboplatin ve Gemsitabin ile Kombinasyonlarının Araştırılması. *II. Multidisipliner Kanser Araştırma Sempozyumu.* 24-27 February 2008, Uludag, Bursa.

48-Yılmaztepe A, Zık B, Yağcı A, Sevimli A, Yılmaz M, Karadağ M, Ursavaş A, Akgöz S, Tokullugil A, **Ulukaya E**. Akciğer kanserli hastalarda TRAIL-R1 ekspresyonu. *II. Multidisipliner Kanser Araştırma Sempozyumu.* 24-27 February 2008, Uludag, Bursa.

49-Arı F, Yılmaztepe AO, Özel MZ, Kutlular Ö, **Ulukaya E**. The differential anticancer effects of green tea in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines. *II. Multidisipliner Kanser Araştırma Sempozyumu.* 24-27 February 2008, Uludag, Bursa.

50- Ulukaya E. Advanced practical course in mammalian cell biology. May 25-June 4 2009, Gebze, İzmit.

51- Ulukaya E. Sitotoksisite testlerinde güncel durum. *XI. Ulusal Tıbbi Biyoloji ve Genetik Kongresi.* 28-31 October 2009. Bodrum (Invited speaker)

52- Ulukaya E. İleri moleküler hücre biyolojisi teknikleri uygulamalı eğitimi. *Tübitak.* 13-17 October 2010 (Invited speaker)

52- Ulukaya E, Vatansver S. Apoptozisin tıp bilimindeki yer. 14-17 October 2010. *36. Ulusal Fizyoloji Kongresi.* Edirne (Invited speaker)

53- Ulukaya E. Uludag UNİVERSİTYnce Yeni Sentezlenen Terpiridin İçeren Palladium(II) ve Platinum(II) Sakkarinat Komplekslerinin Antikanser Etkilerinin ve Mekanizmalarının Araştırılması. *19 Ulusal Kanser Kongresi.* 20-24 April2011, Antalya. (Oral presentation)

54- Yeğin DA, Açılan C, Oral AY, Kale Ş, Arı F, **Ulukaya E**. Meme Kanserinde Verapamil'in Dosetaksol, Gemsitabin ve Karboplatin İle Kombinasyonunun Sitotoksik Etkilerinin İn Vitro Araştırılması. *19 Ulusal Kanser Kongresi.* 20-24 April2011, Antalya. (Poster)

55- Ulukaya E. İleri moleküler hücre biyolojisi teknikleri uygulamalı eğitimi. *Tübitak.* 12-16 September 2011 (Invited speaker)

56- Ulukaya E. Kanser kök hücre kavramı. *Tıbbi Onkoloji Kongresi.* Antalya, 2012. (Invited speaker)

57- Ulukaya E. Yeni Hücre Ölümü Biyobelirteçlerinin Onkolojideki Yeri. Ege onkoloji günleri. Özdere, 2012. (Invited speaker)

58- Belkis Nihan Coşkun, Osman Manavoğlu ve **Engin Ulukaya.** Akciğer kanseri hastalarında yalnızca apoptozun değil, total hücre ölümünün ölçülmesi taksan-bazlı kemoterapiye yanıt için daha iyi bir belirteç midir? Tıbbi Onkoloji Kongresi. Antalya, 2012. (Oral presentation)

59- Ulukaya E. Kanserde metilasyon. VIII. Klinik Biyokimya Uzmanlar Derneği Kongresi. Bodrum. 18-22 September 2012. (Invited speaker)

60- Ulukaya E. Cancer Stem Cell. 1. Kırgızistan Biyoloji Kongresi. Bişkek. 24-27 September 2012. (Invited speaker)

61- Ulukaya E. Sitotoksikite testlerine bilinçli yaklaşım: Güvenmek veya güvenmemek. 21. Ulusal Biyoloji Kongresi. İzmir. 3-7 September 2012. Invited speaker

62- Ferda Arı, Didem Karakaş, Buse Cevatemre, Melis Debreli Coşkun, Engin Ulukaya. Bitki Ekstraktlarında Kullanılan MTT Metodu Ne Kadar Güvenilir?(Oral presentation). Ulusal Biyoloji Kongresi. 3-7 September 2012, İzmir

63- Ferda Arı, Seyhan Oran, Sule Öztürk, Serap Çelikler, Engin Ulukaya. *Parmelia sulcata*'nın Farklı Kanser Hücreleri Üzerindeki Sitotoksik/Apoptotik Etkileri. (Oral presentation). Ulusal Biyoloji Kongresi. 3-7 September 2012, İzmir

64- Mehmet Sarımahmut, Buse Cevatemre, Nazlıhan Aztopal, Melis Debreli Coşkun, Engin Ulukaya. Fenretinid ve TRAIL Kombinasyonu Tedavisinin Meme Kanseri Hücre Soyları Üzerindeki Sitotoksik/Apoptotik Etkilerinin Araştırılması. (poster). Ulusal Biyoloji Kongresi. 3-7 September 2012, İzmir

65- Buse Cevatemre, Ferda Arı, Arzu Yılmaztepe Oral, Mehmet Sarımahmut, Egemen Dere, Engin Ulukaya. Meme Kanseri Tedavisinde Ümit Vaat Edici Yeni Bir Kombinasyon:Fenretinid ve İndol-3-karbinol. (poster). Ulusal Biyoloji Kongresi. 3-7 September 2012, İzmir

66- Nazlıhan Aztopal, Buse Cevatemre, Arzu Yılmaztepe Oral, Egemen Dere, Serap Çelikler, Engin Ulukaya. *Pelargonium quercetorum* Ekstraktının Sitotoksik Etkisinin Akciğer Kanseri Hücrelerinde in vitro Araştırılması. (poster). Ulusal Biyoloji Kongresi. 3-7 September 2012, İzmir

67- Didem Karakaş, Ferda Arı, Nazlıhan Aztopal, Arzu Yılmaztepe Oral, Mehmet Sarımahmut, Veysel Turan Yılmaz, Engin Ulukaya. Yeni Sentezlenen Pd (II) ve Pt (II) Sakkarinat Komplekslerinin Anti-kanser Etkilerinin ve Mekanizmalarının Araştırılması. (poster). Ulusal Biyoloji Kongresi. 3-7 September 2012, İzmir

68- Melis Debreli Coşkun, Engin Ulukaya, Didem Karakaş, Buse Cevatemre, Nazlıhan Aztopal, Mehmet Sarımahmut, Arzu Yılmaztepe Oral, Ferda Arı, Hatice Mehtap Kutlu. Yeni Sentez Edilen Palladyum (II) Bileşiğinin H-ras 5RP7 ve NIH/3T3 Hücre Hatları Üzerindeki Sitotoksik Etkileri. (poster). Ulusal Biyoloji Kongresi. 3-7 September 2012, İzmir

69- Zelal Adiguzel, Tarik Baykal, Muge Serhatli, Omer Kacar, Veysel Yılmaz, Engin Ulukaya, Ceyda Acilan. Yeni bir paladyum (II) kompleksine yanıt olarak göğüs kanseri hücrelerinde meydana gelen moleküler değişikliklere proteomik yaklaşım. (poster) XXIV. Ulusal Biyokimya Kongresi, 25-28 September 2012, Konya

70- Ulukaya E. Sitotoksikite testlerine bilinçli yaklaşım. Hücre Ölümü Derneği Çalıştayı. 1-2 November 2012, Eskişehir. Invited speaker

71- Ulukaya E. Kanser Kök Hücre. IV. Multidisipliner kanser araştırma kongresi. 13-16 December 2012, Bursa (Speaker)

72- Ulukaya E. Individualized tumor response test. 1st. Oncology meeting. 4 Feb 2013. Georgia. (Invited speaker)

73- Omer Kacar, Zelal Adiguzel, Veysel T. Yılmaz, Yuksel Cetin, Buse Cevatemre, Nazli Arda, Engin Ulukaya and Ceyda Acilan, Bir antikanser ajan olan paladyum II bileşiğinin etkisinin insan kanser hücre hatlarında in vitro olarak incelenmesi , 1. İlaç kimyası, üretimi, teknolojisi, standardizasyonu kongresi, 29-31 March 2013, Antalya

74- Zelal Adiguzel, Tarik Baykal, Omer Kacar, Didem Karakas, Muge Serhatli, Engin Ulukaya, Veysel T. Yılmaz, Ceyda Acilan, Yeni bir Pd(II) bileşiğinin DNA kırıkları üzerinden oluşturduğu moleküler etkinin biyokimyasal ve proteomik metotlarla incelenmesi, 1. İlaç kimyası, üretimi, teknolojisi, standardizasyonu kongresi, 29-31 March 2013, Antalya

75- Ulukaya E. Frame FF, Cevatemre B, Yılmaz VT, Maitland NJ. Metastatik Prostat Kanseri Tedavisinde Ümit Vaat Edici Yeni bir Bileşik: Uludag UNİVERSİTYnce Sentez Edilen Yeni Palladium Bileşiğinin Kanser Kök Hücreleri Üzerindeki Sitotoksik Etkisi. 20. Ulusal Kanser Kongresi. 19-23 April2013, Antalya

76- Ulukaya E. Coskun MD, Karakas D, Cevatemre B, Kutlu HM, Oral AY, Yılmaz VT. Sarkom tedavisi için yeni bir yaklaşım:Uludag UNİVERSİTY tarafından yeni sentez edilen palladyum (II) bileşiği. 20. Ulusal Kanser Kongresi. 19-23 April2013, Antalya

77- Cevatemre B, Ari F, Sarimahmut M, Yilmaztepe AO, Dere E, Kaçar Ö, Adigüzel Z, Açılan C, **Ulukaya E.** Meme kanseri tedavisinde ümit vaat edici yeni bir kombinasyon:Fenretinid ve indol-3-karbinol. 20. Ulusal Kanser Kongresi. 19-23 April2013, Antalya

78- Ulukaya E. Kanser kök hücre. I. Biyomühendislik ve Genetik Günleri. Üsküdar UNİVERSİTY, Nermin Tarhan Konferans Salonu. 3-4 May 2013. Invited speaker

79- Ulukaya E. Sitotoksisite testleri. Hücre ölüm yöntemleri kursu. Certificate program. DETAE, İstanbul. 26-28 June 2013 (Educator)

80- Ulukaya E. Kanserin tanı tedavi ve izleminde metilasyonun/epigenetiğın rolü. Türk Biyokimya Kongresi. 3-7 September 2013, İzmir (Invited speaker)

81- Ulukaya E. Cancer Stem Cell. 3rd Geneocell summer school. 9-15 September 2013. Kocaeli UNİVERSİTY, Kocaeli. (Invited speaker)

82- Şeniz Korkmaz, **Engin Ulukaya**, Mehmet Sarimahmut2, Buse Cevatemre2, Arzu Yilmaztepe Oral. Zeytin yaprağı ekstrelerinin insan meme kanserinde epirübisinin etkinliğini fenotipe göre modifiye etmesi. Türk Biyokimya Kongresi. 3-7 September 2013, İzmir

83- Ulukaya E. Cancer Stem Cell. International multidisciplinary symposium on drug research and development. 28-30 November 2013, Antalya (Invited speaker)

84- Ulukaya E. Kanser Kök Hücre Kavramı ve Klinik Yansıması. 5. Bilim UNİVERSİTY Onkoloji Günleri. 20-22 December2013, Sapanca (Invited speaker)

85- Cevatemre B, Ari F, Sarimahmut M, **Ulukaya E.** Detection of apoptosis by M30 assay in vitro is not reliable in the cancer cells expressing low level of cytokeratin. EU COST CMST Action CM 1106, Working Groups Meeting. 30 Jan- 1 Feb 2014, Amsterdam

86- Ulukaya E. Kanser Kök Hücre. 1. Kök hücre ve hücrel tedaviler kongresi 20-23 March2014, Kocaeli (Invited speaker)

87- Ulukaya E. Kanser kök hücre ve direnç. Hedef Kanser 2014 Kongresi. 17-20 April2014. Girne, Kıbrıs (Invited speaker)

88- Ulukaya E. Cancer cells from a clinical perspective. Novel fluidic Technologies and applications with an emphasis on collaboration workshop. 21-22 April 2014. İzmir (Invited speaker)

89- Ulukaya E. Kanser kök hücre ve klinik yansıması. EACR-sponsored 2nd anticancer agents congress and 5th multidisciplinary cancer research congress. 23-27 April 2014. Bodrum. (Invited speaker)

90- Buse Cevatemre, Didem Karakaş, Arzu Yilmaztepe Oral, Veysel Turan Yılmaz, Engin Ulukaya. Palladium (II) kompleksinin tek başına ve ilaç kombinasyonları ile meme kanseri kök hücreleri üzerindeki sitotoksik etkilerinin in vitro incelenmesi. EACR-sponsored 2nd Anticancer Agents Congress & V. Multidisipliner Kanser Araştırma Kongresi . 23-27 April2014, Mugla.

91- Didem Karakaş, Nazlıhan Aztopal, Ferda Arı, Veysel Turan Yılmaz, Engin Ulukaya. Palladium (II) komplekslerinin akciğer ve kolon kanseri hücre soyları üzerine sitotoksik/apoptotik etkileri. EACR-sponsored 2nd Anticancer Agents Congress & V. Multidisipliner Kanser Araştırma Kongresi . 23-27 April2014, Mugla.

92- Nazlıhan Aztopal, Didem Karakaş, Ferda Arı, Veysel Turan Yılmaz, Engin Ulukaya. Yeni sentezlenen Palladium komplekslerinin akciğer kanseri hücre soyu üzerine sitotoksik/apoptotik etkileri. EACR-sponsored 2nd Anticancer Agents Congress & V. Multidisipliner Kanser Araştırma Kongresi. . 23-27 April2014, Mugla.

93- Merve Erkısa, Şeyma Aydınlık, Ferda Arı, Veysel Turan Yılmaz, Engin Ulukaya. Palladium (II) komplekslerinin kemoterapötik ajanlarıyla kombinasyonun kolon kanserinde sitotoksik/sitostatik etkilerinin in vitro araştırılması. EACR-sponsored 2nd

Anticancer Agents Congress & V. Multidisipliner Kanser Araştırma Kongresi. . 23-27 April2014, Mugla.

94- Ulukaya E. Karakaş D. Cevatemre B. Aztopal N. Arı F. Yılmaz VT. Palladyum(II) kompleksi ve niklozamid kombinasyonunun meme kanseri kanser kök hücreleri üzerindeki in vitro güçlü sitotoksik/apoptotik etkisi. 21. Ulusal Kanser kongresi. 22-26 April2015. Antalya (Oral presentation)

95- Ulukaya E. Karakaş D. Kurt E. KEMOREFRAKTER İLERİ EVRE MEME KANSERİ TEDAVİSİNDE TÜMÖR KEMOSENSİTİVİTE TESTİ (ONKOGRAM®): YENİ BİR UMUT. 21. Ulusal Kanser kongresi. 22-26 April2015. Antalya (Poster)

96- Cevatemre B. Karakaş D, Sarımahmut M. Oral AY. **Ulukaya E** M30 ÜNİVERSAL BİR APOPTOZİS BİYOBELİRTECİ MİDİR ?. 21. Ulusal Kanser kongresi. 22-26 April2015. Antalya (Poster)

97- Ulukaya E. Apoptozis ve kanser ilişkisi. 23. Ulusal Farmakoloji Kongresi. 7-10 September 2015. Ankara (Invited speaker)

98- Ulukaya E. Temel ve Klinik Kanser Araştırmada Yeni ve Tehlikeli Aktörler: Kanser Kök hücreleri. 27. Ulusal Biyokimya Kongresi. 3-7 November2015. Antalya (Invited speaker)

99- Merve Erkisa, Şeyma Aydınlık, Buse Cevatemre, Nazlıhan Aztopal, Ferda Arı, Veysel Turan Yılmaz, **Engin Ulukaya.** 27. Ulusal Biyokimya Kongresi. 3-7 November2015. Antalya (Poster presentationu ve poster ödülü)

100- Ulukaya E. Onkogram. 11. Ulusal onkolojik araştırmalar çalıştayı. 12-15 November2015. Antalya (**Invited speaker**)

101- Ceyda ACILAN, Buse CEVATEMRE, Zelal ADIGUZEL, Didem KARAKAS, **Engin ULUKAYA,** Nádia RIBEIRO, Isabel CORREIA *, João Costa PESSOA. YENİ BAKIR KOMPLEKSLERİNİN SENTEZİ, MOLEKÜLER ETKİ MEKANİZMASI, DNA HASARI OLUŞUMU ve P53-BAGIMSIZ APOPTOTİK ETKİLERİ. SANKO University Innovation in Medicine Summit-2, 5th-7th May 2016, Gaziantep, Turkey (Poster)

102- Ulukaya E. Serum apopitoz belirteçlerinin onkoloji kliniğindeki önemi. Uluslararası katılımlı kongre & lab. Expo2016. 27 September-1 October 2016, Trabzon (Speaker)

2017

103- Ulukaya E. Tehlikeli aktörler: kanser kök hücreleri. 1. BİYOM günleri. Yıldız Teknik UNİVERSİTY. 25 May 2017. İstanbul (Invited speaker)

104- Ulukaya E. Gliomlar ve Kanser Kök Hücreleri. TURNOG-Glial tümörlerde nöroonkolojik araştırma çalıştayı. 6-7 May 2017. Kayseri (Invited speaker)

105- Nazlıhan Aztopal, Merve Erkisa, Ferda Ari, Egemen Dere, **Engin Ulukaya.** Meme Kanseri Kök Hücrelerinde Wnt ve HDAC İnhibisyonu ile Apoptozisin Uyarılması. İstinye UNİVERSİTY Moleküler Kanser Zirvesi. 25-26 March2017. İstanbul

106- Engin Ulukaya. TURNOG Glial tümörlerde nöroonkolojik araştırma çalıştayı. Gliomlar ve kanser kök hücreleri. 6-7 May 2017. Kayseri (Invited speaker)

107- Engin Ulukaya. Hücre Ölümü/Sitotoksikite Araştırmalarında Yapılan Hatalar ve Dikkat Edilecek Özellikler. 28. Ulusal Biyokimya Kongresi. 19-23 September 2017. Erzurum (Invited speaker)

108- Engin Ulukaya. Yeni Araştırmalar ve Kanser(siz) Gelecek. Health 4.0: Sağlıkta yenilikler kongresi. 24-26 November2017. İstanbul (Invited speaker)

109- Engin Ulukaya. Kanser ilaç geliştirme çalışmaları: kendi fırsatını oluşturmak. EEMKON 2017. 16-18 November2017. İstanbul (Invited speaker)

7.7. Other publications

1- Tokullugil AH, Dirican M, **Ulukaya E.** (Translation editor) Biochemistry (Lippincott's Illustrated Reviews, Biochemistry 2nd Edition: Champe PC, Harvey RA). Nobel Tıp Kitabevleri, İstanbul, 1997 (440 page).

2- Ulukaya E Clinical Biochemistry (Clinical Biochemistry for Medical Students. Laker MF). Güneş-Nobel Tıp Kitabevleri, Bursa, 1998 (343 page). (Translation editor)

3- Ulukaya E. Clinician's Guide to Laboratory Medicine. Nobel-Güneş Kitabevleri, Bursa, 2004 (875 page). (Translation editor)

Biochemistry (Lippincott's Illustrated Reviews, Biochemistry 2nd Edition: Champe PC, Harvey RA). Translation editor: Tokullugil AH, Dirican M, **Ulukaya E.** Nobel Tıp Kitabevleri, İstanbul, 1997. (Translation on book chapter)

4- Clinical Biochemistry (Clinical Biochemistry for Medical Students: Laker MF). Translation editor: **Ulukaya E.** Güneş-Nobel Tıp Kitabevleri, Bursa, 1998. (Translation on book chapter)

5- Medikal Onkoloji ve Kanser Biyolojisinin Temelleri. Engin Ulukaya. Manual of Clinical Oncology: Dennis A. Casciato and Barry B. Lowitz (Eds). Part I.1. Lippincott Williams and Wilkins, Philadelphia, USA pp: 3-28, 2000. (Translation on book chapter)

6- Biochemistry (Harper' Biochemistry. Murray RK, Granner DK, Mayes PA and Rodwell VW. 25th Edition). Zenobiyotiklerin metabolizması. Nobel Tıp Kitabevleri. Bursa. pp: 780-786, 2004. (Translation on book chapter)

7- Ulukaya E. İdrar. Tıp Öğrencileri İçin Biyokimya Uygulama Kitabı. Tokullugil AH, Dirican M, Ulukaya E. Güneş-Nobel Tıp Kitabevleri, Bursa, pp: 85-107, 1997. (Book Chapter)

8- Ulukaya E. Hücre siklusu ve apoptozis. Akciğer Kanserleri: Tanı ve tedavide temel ilkeler ve uygulamalar. Avrupa Tıp Kitapçılık Ltd. Şti. İstanbul, TURKEY. pp. 26-38, 2001. (Book Chapter)

9- Ulukaya E, Çolakoğulları M. Kemik ve Yumuşak Doku Tümörlerinde Moleküler Biyoloji. Kemik ve Yumuşak Doku Tümörleri. Engin K, Sağlık Yener ve Aydın U (Editor). Nobel Tıp Kitabevleri. İstanbul, pp: 15-25, 2005. (Book Chapter)

10- Ulukaya E. Lippincott's illustrated reviews. 5th Edition. Wolters Kluwer Business. Baltimore, USA. 2014

8. Projects

	PROJECT NAME	INSTITUTION	BUDGET (TL)	DATE	TASK	PROJECT TYPE	ARDEB NO
1	Akciğer Kanserlerinde Fas, Survivin ve Kaspaz-3'ün Tedaviye Yanıtla İlişkisinin İncelenmesi	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	22.000	2002	CO-INVESTIGATOR	Institutive (BAP)	2002/36
2	Akciğer Kanserlerinde Trail-R1 ve VEGF-R1'in Tedaviye Yanıtla İlişkisinin İncelenmesi	Uludag UNİVERSİTY Bilimsel	25.000	2002	CO-INVESTIGATOR	Institutive (BAP)	2002/37

		Araştırma Projeleri					
3	Akciğer Kanselerinde M30'un Tedaviye Yanıtla İlişkinin İncelenmesi	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	30.000	2002	PROJECT COORDINATOR	Institutive (BAP)	2002/38
4	Kanser Olgularının Tedaviye Yanıtının ATP-TCA ve MTT Metodu İle ex vivo Olarak Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	298.000	2004	PROJECT COORDINATOR	Institutive (BAP)	T-2004 / 1
5	FEC Tedavisi İle Kombine Olarak Gen Metilasyonunu İnhibe Edici Ajan Kullanımının Meme Kanseri Tedavisindeki Yerinin İn Vitro Araştırılması: Yeni Bir Tedavi Seçeneği Olasılığı?	TÜBİTAK	25.000	2007	PROJECT COORDINATOR	TÜBİTAK	106S349 Completed!
6	Sitokin Gen Polimorfizminin Akciğer Kanselerindeki Rolü ve Tedaviye Yanıtla İlişkisi	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	10.000	2004	PROJECT COORDINATOR	Institutive (BAP)	T-2004 / 14
7	Proteozom inhibitörü velcade'nin 4T1 kanser hücrelerinde uyardığı p53-bağımsız apoptozisin araştırılması.	TÜBİTAK	210.000	2009	CO-INVESTIGATOR	TÜBİTAK	109S035 Completed!
8	FEC Tedavisinin Meme Kanselerindeki Etkinliğinin Arttırılmasında Potansiyel Socs1 Ve Socs3 Modüle Edici Ajanların Rolü	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	97.000	2009	CO-INVESTIGATOR	Institutive (BAP)	TIP-2009/8
9	Kırıkkale UNİVERSİTY Merkezi Araştırma Laboratuvarları (KÜMAL)	Kırıkkale UNİVERSİTY	6.500.000	2009	PROJECT ADVISOR	DPT	2009K120910
10	Meme ca'lı hastalarda kemoterapi etkinliğinin ex vivo olarak değerlendirilmesi	Kocaeli UNİVERSİTY Kök Hücre Araştırma Merkezi	20.000	2009	CO-INVESTIGATOR	KOU BAP	2009/1
11	Bazı yeni 3,5-disubstitüe-1,2,4-oxadiazol türevlerinin sentezi ve biyolojik aktivitelerinin belirlenmesi.	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	60.000	2010	CO-INVESTIGATOR	Institutive (BAP)	UAP(F)-2010/24
12	Uludag UNİVERSİTYnce Yeni Sentezlenen Bis(piridin-2-il metil)amin İçeren Platin(II) ve Palladyum(II)-Sakkarinat Komplekslerinin Meme Kanseri Üzerindeki Antikanser Etkilerinin ve Mekanizmalarının İn Vitro Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	65.000	2010	PROJECT COORDINATOR	Institutive (BAP)	UAP(T)-2010/6
13	Fenretinid ve TRAIL Kombinasyonu Tedavisinin Meme Kanseri Hücre Soyları Üzerindeki Sitotoksik/Apoptotik Etkilerinin Araştırılması: Meme Kanselinin Tedavisinde Ümit Verici Yeni bir Yaklaşım	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	120.000	2010	PROJECT COORDINATOR	Institutive (BAP)	UAP(T)-2010/37
14	Akciğer kanserli hastalarda prognostik ve prediktif biyobelirteçlerin serum	Uludag UNİVERSİTY Bilimsel	21.980	2010	CO-INVESTIGATOR	Institutive (BAP)	UAP(T)-2010/39

	düzeylerinin incelenmesi ve tedaviye cevap ile ilişkisi	Araştırma Projeleri					
15	Fenretinid ve İndol-3-karbinol Kombinasyonunun Meme Kanseri Hücre Soyları Üzerindeki Sitotoksik/Apoptotik Etkilerinin Araştırılması.	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	19.982	2011	CO-INVESTIGATOR	Institutive (BAP)	UAP(F)-2011/44
16	Endemik <i>Centaurea fenclii</i> Reichardt türünün kolon ve meme kanseri hücre dizileri üzerindeki sitotoksik ve apoptotik etkisi	TÜBİTAK	325.214	2010	CO-INVESTIGATOR	TÜBİTAK	110T905
17	Uludag UNİVERSİTYnce Yeni Sentezlenen Piridin ve 3-asetilpiridin içeren palladyum(II) ve platin(II) Sakkarinat Komplekslerinin Meme Kanseri Üzerindeki Antikanser Etkilerinin ve Mekanizmalarının <i>in vitro</i> Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	80.000	2011	CO-INVESTIGATOR	Institutive (BAP)	UAP(T)-2011-14
18	Yeni Sentezlenen Palladyum(II) Kompleksinin [PdCl(terpy)](sac).2H ₂ O] Meme Kanseri Üzerindeki Antikanser Etkisinin ve Mekanizmalarının <i>in vitro</i> Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	15.000	2011	CO-INVESTIGATOR	Institutive (BAP)	UAP(F)-2011/41
19	Bursa ve Çevresinde Yayılış Gösteren <i>Lobaria pulmonaria</i> (L.) Hoffm., <i>Usnea rigida</i> (Ach.) Röhl. ve <i>Xanthoparmelia somloensis</i> (Gyeln.) Hale'in Sitotoksik ve Genotoksik/Antigenotoksik Etkilerinin <i>In Vitro</i> Test Yöntemleri İle Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	20.000	2011	CO-INVESTIGATOR	Institutive (BAP)	UAP(F)-2011/42
20	Piridin Bazlı Ligantlar İçeren 5,5-Dietilbarbitürat Palladyum(II) Ve Platin(II) Komplekslerinin Sentezi, Karakterizasyonu Ve Anti-Kanser Özellikleri	TÜBİTAK	243.558	2011	CO-INVESTIGATOR	TÜBİTAK	111T099 Completed!
21	Yeni Sentez Edilen Palladyum (II) Komplekslerinin Transforme Fibroblastlar Üzerindeki Etkilerinin İncelenmesi	Anadolu UNİVERSİTY BAP	9.810	2012	CO-INVESTIGATOR	Institutive (BAP)	1110F164
22	Uludag UNİVERSİTYnce Sentezlenen Palladium (II) Kompleksi [PdCl(terpy)](sac).2H ₂ O ile Sık Kullanılan Kanser İlaç Kombinasyonlarının Sitotoksik/Apoptotik Etkilerinin Meme Kanseri Kök Hücrelerinde <i>In Vitro</i> Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri	70.000	2012	CO-INVESTIGATOR	Institutive (BAP)	OUAP(T) 2012/2
23	Akciğer Kanseri Hücre Hatları Üzerine <i>Wiedemannia</i>	Uludag UNİVERSİTY	23.400	2012	CO-INVESTIGATOR	Institutive (BAP)	UAP (F) 2012/17

	<i>orientalis</i> 'in Sitotoksik Aktivitesinin Araştırılması	Bilimsel Araştırma Projeleri					
24	Uludag UNİVERSİTYnce Yeni Sentezlenen Platin (II) Kompleksinin [Pt(hepy) ₂ Cl ₂] Sitotoksik/Apoptotik Etkilerinin Meme Kanseri Kök Hücrelerinde <i>In Vitro</i> Araştırılması	TÜBİTAK	25.000	2012	CO- INVESTIGATOR	TÜBİTAK	112T726 Completed!
25	Uludag UNİVERSİTYnce sentez edilen palladium (II) kompleksinin ve kök hücre yolak inhibitörleri ile kombinasyonlarının meme kanseri kanser kök hücreleri üzerindeki sitotoksik/genotoksik etkilerinin ve mekanizmanın gen ve protein düzeyinde araştırılması	TÜBİTAK (COST Projesi, CM 1106)	278.050	2012	PROJECT COORDINATOR	TÜBİTAK	212T147 Completed!
26	Prostat Kanserinde Palladyum(II) Kompleksinin Tüm Genom Ekspresyonu Üzerine Etkisinin Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri (PROJECT COORDINATOR : Hale Samlı)	43.886	2013	CO- INVESTIGATOR	Institutive (BAP)	OUAP(V)- 2013/
27	<i>Astragalus sibthorpianus</i> Boiss. Bitkisinin Meme Kanseri Hücre Soylarında Sitotoksik, Apoptotik ve Genotoksik/Antigenotoksik Etkilerinin Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri (PROJECT COORDINATOR : Mehmet Sarımahmut. BAP hızlı proje)		2013	CO- INVESTIGATOR	Institutive (BAP)	HDP(F)- 2013/28
28	Cisplatin, Yeni Palladium Kompleksi ve Paclitaxel'in Balb-c Farelerde Ehrlich Ascites (EAC) Tümöründe Proliferasyon ve Apoptoz Üzerine Olan Etkisi	Istanbul UNİVERSİTY BAP (PROJECT COORDINATOR : Elif Armutak)	19.985	2013	CO- INVESTIGATOR	Institutive (BAP)	Proje No: 30869
29	Meme Kanserinde Otofaji inhibitörlerinin Doksorubisin ile Kombinasyonu Sonucu Kemoterapötik Ajanların Duyarlılığının Arttırılmasının İn Vitro Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri (PROJECT COORDINATOR : Egemen Dere)	25.000 TL	2013	CO- INVESTIGATOR	Institutive (BAP)	OUAP(F)- 2013/43
30	Usnea filipendula Stirt. Liken Türünün Sitotoksik ve Apoptotik Aktivite-sinin Meme Kanseri Hücre lerinde Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri (PROJECT COORDINATOR : Ferda Arı. BAP hızlı proje)	25.000 TL	2013	CO- INVESTIGATOR	Institutive (BAP)	HDP(F)- 2013/27
31	Uludag'ın Bitki Potansiyelinin Antikanser İlaç Özellikleri Açısından Taranması ve Korunması	Uludag UNİVERSİTY BURSA Büyükşehir	25.000 TL	2013	PROJECT COORDINATOR	Institutive	Proje No Yok

		Belediyesi Ortak İşbirliği Projesi					
32	Akciğer Kanseri Olgularının Tedaviye Yanıtının ATP-TCA ve MTT Metodu ile ex vivo Olarak Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma Projeleri (PROJECT COORDINATOR : Ender Kurt)	70.000 TL	2013	CO-INVESTIGATOR	Institutive (BAP	OUAP(T)-2014/2
33	Yeni Palladium Kompleksi ve Paclitaxel'in Balb-c Farelerde Ehrlich Ascites (EAC) Tümöründe Proliferasyon ve Apoptoz Üzerine Olan Etkisi	Istanbulbul UNİVERSİTY Bilimsel Araştırma Projeleri (PROJECT COORDINATOR : Elif İlkay Armutak)	19.985 TL	2013	CO-INVESTIGATOR	Institutive (BAP	Prj No: 30869
34	Akciğer kanserinde M30'un tedaviye yanıtla ilişkisinin in vitro araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma	24.335 TL	2014	PROJECT COORDINATOR	Institutive (BAP	KUAP(T)-2014/1
35	Kanser kök hücrelerine özgü hücre canlılık testi geliştirilmesi	Uludag UNİVERSİTY Bilimsel Araştırma	69.619 TL	2014	PROJECT COORDINATOR	Institutive (BAP	OUAP(T)-2014/1
36	Magnetik demir nanopartiküllerine yüklenmiş siklopaminin insan meme kanseri kök hücreleri üzerindeki sitotoksik/apoptotik etkilerinin araştırılması.	Uludag UNİVERSİTY Bilimsel Araştırma	133.460 TL	2014	CO-INVESTIGATOR	Institutive (BAP	BUAP(F)-2014/3
37	Malign ve Sağlıklı Akciğer Hücrelerinde Oksidatif DNA Hasarı Markör Ürünlerinin Belirlenmesi ve Hasar Oluşumunu Antioksidanların Baskılama Mekanizmalarının Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma	150.000 TL	2014	CO-INVESTIGATOR	Institutive (BAP	2014/5
38	Vimentin, fibronektin, NGAL,osteopontin, ALCAM ve prominin serum düzeylerinin, meme kanserinin tanısı, kemoterapiye yanıtı ve prognozuyla ilişkisi	Uludag UNİVERSİTY Bilimsel Araştırma (PROJECT COORDINATOR : Asuman Tokullugil)	24.490	October2014 (2 year)	CO-INVESTIGATOR	Institutive (BAP	KUAP(T)-2014/38
39	Bazı metal iyonlarının fenolik ligandlar ile oluşturdukları komplekslerin sentezi, karakterizasyonu, antioksidan ve antikanser özelliklerinin araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma (PROJECT COORDINATOR : Hasane Mutlu Gençkal	67.620	2014	CO-INVESTIGATOR	Institutive (BAP	OUAP(F)-2014/27
40	Olası Bir Anti-Kanser Bileşik: Terpiridin İçeren Palladyum(II) Sakkarinat Kompleksinin {[Pd(sac)(terpy)](sac)} Meme Kanseri Hük Hücreleri Üzerindeki Sitotoksik/Sitostatik Etkilerinin ve Mekanizmalarının Araştırılması	TÜBİTAK	233.452	2014 (2 year)	PROJECT COORDINATOR	TÜBİTAK	114Z269

41	Kanser Tedavisinde Kullanılan Kemoterapötik İlaçların Hassasiyetinin Belirlenmesi	Erzurum UNİVERSİTY Eczacılık Fakültesi PROJECT COORDINATOR : Ali Aşçı	30.000	10/07/2014 (1 year)	CO-INVESTIGATOR	Institutive (BAP)	2014034
42	Pankreas epitel hücrelerinin onkojenik transformasyonunda PFKFB2'nin rolü	TÜBİTAK	399.041	01/10/2014 (3 year)	CO-INVESTIGATOR	TÜBİTAK	114Z496
43	Doksorubisin Ve Klorokin Kombinasyonunun Fare Meme Tümörü Ehrlich Ascites Karsinoma (Eac) Üzerine Etkisinin In Vitro Ve In Vivo Değerlendirilmesi	TÜBİTAK	59.982,15	March 2015 (18 month)	Danışman	TÜBİTAK 3001	214S609
44	Pirüvat Dehidrojenaz Enzim Kompleksinin Epitelyal Mezenkimal Dönüşüm (Emd) İle İlişkisinin In Vitro Araştırılması	TÜBİTAK PROJECT COORDINATOR : Buse Cevatemre	30.000	March 2015 (12 month)	CO-INVESTIGATOR	TÜBİTAK 1002	115Z124
45	Meme Kanseri Kök Hücrelerinde Bazı miRNA'ların Etkinliklerinin Araştırılması	ÖNAP, İstanbulbul UNİVERSİTY PROJECT COORDINATOR : Prof. Dr. Şakir Ümit Zeybek	60.644.00 TL	August 2015 (12 month)	CO-INVESTIGATOR	Institutive (BAP)	52677
46	Yeni sentez edilen palladyum (II) bileşiğinin otofaji inhibitörleri ile kombinasyonunun prostat kanser hücreleri üzerindeki sitotoksik etkisinin araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma	70.000.00 TL	August 2015 (12 month)	PROJECT COORDINATOR	Institutive (BAP)	OUAP(T)-2015/19
47	Meme kanseri kanser kök hücrelerinde bir hİstanbul deasetilaz inhibitörü olan valproik asidin sinyal ileti, apoptozis ve DNA tamir mekanizmalarında önemli olan genlerin metilasyon seviyesine etkisinin araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma (PROJECT COORDINATOR : Asuman Tokullugil)	25.000	2015	CO-INVESTIGATOR	Institutive (BAP)	KUAP(T)-2015/6
48	Salvia candidissima Vahl. Bitkisinin İnsan Meme Kanseri Hücrelerindeki Antikanser Aktivitesinin Araştırılması	Uludag UNİVERSİTY Bilimsel Araştırma	2.500	2015	PROJECT COORDINATOR	Institutive (BAP)	HDP(T)-2015/32
49	Fosfin Ligantları İçeren Yeni Palladyum(II) ve Platin(II) Sakkarinat Komplekslerinin Sentezi, Yapısal Karakterizasyonu, DNA/Protein Bağlanma, Moleküler Doking ve Antikanser Özelliklerinin Araştırılması	Tübitak 1001	?	01.10.2016 24 month	CO-INVESTIGATOR	TÜBİTAK	215Z230
50	Kök Hücre Wnt Yolak İnhibitörü olan Niklozamidin Antikanser İlaçlarla Kombinasyonlarının Meme Kanseri Kanseri Kök Hücreleri Üzerindeki Sitotoksik/Apoptotik Etkilerinin ve Mekanizmanın	Uludag UNİVERSİTY Bilimsel Araştırma	69.000	13.07.2016 24 month	PROJECT COORDINATOR	Institutive (BAP)	?

	Gen ve Protein Düzeyinde Araştırılması						
51	DOKSORUBİSİN VE KLOROKİN KOMBİNASYONUNUN IN VIVO ANTİANJİYOGENİK ETKİSİ	Istanbul UNİVERSİTY BAP	14.838	26.04.2016 24 month	CO- INVESTIGATOR	Institutive (BAP)	TMP-2016- 20856
52	Bir Paladyum (II) [PdCl(terpi)(sak).2H2O] Kompleksinin In Vivo Antianjiyogenik Etkisi	Istanbul UNİVERSİTY BAP	14.838	26.04.2016 24 month	CO- INVESTIGATOR	Institutive (BAP)	TMP-2016- 20595
53	Doksorubisin Klorokin Kombinasyonunun Anjiyogenezde HUVEC Hücrelerinde Tüp Oluşumu Üzerine Etkisi	Istanbul UNİVERSİTY BAP	4.990	31.05.2016 12 month	CO- INVESTIGATOR	Institutive (BAP)	THZ-2016- 21160
54	Elucidation of Molecular Action Mechanisms of Cytotoxic Palladium Derivatives on Various Cancer Cells	Istanbul UNİVERSİTY BAP	4.400	09.06.2016	CO- INVESTIGATOR	Institutive (BAP)	BEK-2016- 21869
55	Paladyum (II) Kompleksinin Anjiyogenez Üzerine Etkilerinin, MTT, ATP/TCA Sitotoksosite Testleri ve Tüp Oluşum Tekniği İle HUVEC Hücrelerinde Araştırılması	Istanbul UNİVERSİTY BAP	19.946,78	29.09.2017 18 month	CO- INVESTIGATOR	Institutive (BAP)	TSA-2017- 24679

9. Administrative Services

10. Professional Affiliations

11. Fellowships and Awards

1-“TRAVEL AWARD” (Boston, USA)

Ulukaya E, Stockwin H, Mehmet H and Wood E J. Fenretinide can Induce Cytochrome c Release from Mitochondria into the Cytosol in Squamous Cell Carcinoma Cells. *The American Society for Biochemistry and Molecular Biology Meeting. Graduate/Postdoctoral Travel Award Program*. 4 June 2000, Boston, USA

2- AWARD OF POSTER (Selcuk, TURKEY)

Ulukaya E, Kurt A, Mehmet H ve Wood EJ. Fenretinide induces apoptosis via cytochrome c release without changing mitochondrial transmembrane potential. *XVI. National Biochemistry Congress. Second International Bioscience Days*. 23-27 October, 2000, Selcuk, TURKEY

3- SCIENCE AWARD

Çağdaş Gazeteciler Derneği Bursa. 2003, Bursa, TURKEY

4- “YOUNG INVESTIGATOR AWARD” (Busan, KORE)

Ulukaya E, Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT tumor chemosensitivity assay. *The 22nd World Congress of Pathology and Laboratory Medicine*. 30 August-3 September, 2003, Busan, KOREA.

5-“THE MOST PROMISING LABORATORY PHYSICIAN” WASPALM MEDAL (Busan, KORE)

Awarded at one of the WasPalm meetings: *The 22nd World Congress of Pathology and Laboratory Medicine*. 30 August-3 September, 2003, Busan, KOREA.

6- EWCD SCHOLARSHIP (Istanbul, TURKEY)

Awarded at the 4th European Workshop on Cell Death. 11-16 May, 2004. Istanbul, TURKEY.

7- AWARD OF TARK 2008 (2.)

S. ULUKAYA, I ALPER, M. KILIÇ, A. YILMAZTEPE, **E. ULUKAYA**. Karaciğer transplantasyonu sırasında oluşan iskemi-reperfüzyon hasarının gösterilmesinde ümit vaat eden yeni serum biobelirteçleri: M30 antijen ve M65 antijen. TARK 2008, 29 October-1 November 2008, Antalya.

8- ‘‘POSTER AWARD’’

INFORMATION AND AR-GE DAYS. ULUDAG UNİVERSİTY. Poster 1. 15-16 November 2011, Bursa

9- ULUDAG UNİVERSİTY BEST PUBLISHING AWARD FOR ANNUAL, 2012

10- ULUDAG UNİVERSİTY THE MOST CITATION OF YEAR AWARD, 2012

11. ULUDAG UNİVERSİTY INFORMATION AND AR-GE DAYS., Poster 1., 13-15 November 2012, Bursa

12. POSTER AWARD (2.)

Kacar O, Adiguzel Z, Yilmaz VT, Cetin Y, Cevatemre B, Arda N, **Ulukaya E**, Acilan C. Investigation of the molecular mechanisms of a palladium(II) saccharinate complex with terpyridine as an anticancer agent. 1st International BAU-drug design symposium. 21-23 March 2013, Istanbul, TURKEY.

13. ULUDAG UNİVERSİTY THE MOST CITATION OF YEAR AWARD, 2013

14. ULUDAG UNİVERSİTY SCIENCE AND ART AWARD, 2013

15. ULUDAG UNİVERSİTY PATENT AWARD, 2013

16. ULUDAG UNİVERSİTY INFORMATION AND AR-GE DAYS Poster 1. 12-14 November 2013, Bursa

17. POSTER AWARD (2.)

Ulukaya E, Sarimahmut M, Karakaş D. SCIENCE AND TECHNOLOGY WEEKLY ACTIVITIES, 12-14 March 2014. Bursa

18. POSTER AWARD (1.)

Omer Kacar, Ibrahim Hatipoglu, Zelal Adiguzel, Veysel T. Yilmaz, Yuksel Cetin, Buse Cevatemre, Nazli Arda, Ahmet T. Baykal, **Engin Ulukaya** and Ceyda Acilan Ayhan. Evaluation of the Molecular Mechanisms of a Palladium(I) Saccharinate Complex with Terpyridine as an Anticancer Agent. 2nd INTERNATIONAL BAU-DRUG DESIGN SYMPOSIUM, 17-19 April 2014, İstanbul

19. POSTER AWARD (1.)

Ferda Ari, Buse Cevatemre, Elif Ilkay Ikitimur, Nazlihan Aztopal, Veysel Turan Yilmaz, **Engin Ulukaya**. Initial mechanism insights of potential anti cancer agent, Palladium (II) saccharinate complex of terpyridine. EACR-Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Mugla.

20. POSTER AWARD (2.)

Elif Ilkay Ikitimur Armutak, Kivilcim Sonmez, Kadriye Akgun Dar, Gulbin Sennazli, Aysegul Kapucu, Funda Yigit, **Engin Ulukaya**. The Effect Of Apoptosis and Anti-Cancer Activity of a Novel Palladium (II) Complex on EAC in Balb-C Mice. EACR-Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Mugla.

21. POSTER AWARD (1.)

ULUDAG UNİVERSİTY BİLGİLENDİRME VE AR-GE GÜNLERİ. Disiplinlerarası çalışma alanında Poster 1. ÖDÜLÜ 11-13 November 2014, Bursa

22. ORAL PRESENTATION AWARD

Arzu Yilmaztepe Oral, Buse Cevatemre, Mehmet Sarimahmut, Ceyda Icel, Veysel Turan Yilmaz, **Engin Ulukaya**. Yeni Sentezlenen Trans-dikloridobis[2-(2-hidroksietil)piridin]platin(II) Kompleksinin Meme Kanseri Hücre Soyları Üzerine Sitotoksik/Apoptotik Etkisi. 3. İlaç Kimyası: İlaç Etkin Maddesi Tasarımı, Sentezi, Üretimi ve Standardizasyonu Kongresi 20-22 March 2015, Antalya

23. ORAL PRESENTATION AWARD

Ulukaya E, Karakas D, Cevatemre B, Aztopal N, Arı F, Yılmaz VT. Palladyum(II) kompleksi ve niklozamid kombinasyonunun meme kanseri kanser kök hücreleri üzerindeki in vitro güçlü sitotoksik/apoptotik etkisi. 21. Ulusal Kanser Kongresi. 22-26 April 2015, Antalya.

24. EACR POSTER AWARD (3.)

Didem Karakas, Buse Cevatemre, Veysel Turan Yilmaz, **Engin Ulukaya**. Trans-Dichloridobis [2-(2 Hydroxyethyl) Pyridine] Platinum(II) Complex Induces Apoptosis via ROS Generation in PC-3 Prostate Cancer Cell Line. EACR-Sponsored 3rd Anticancer Agents Development Congress, 18-19 May 2015, Turkey

25. EACR POSTER AWARD (3.)

Merve Erkisa, SeymaAydnlik, Buse Cevatemre, Nazlıhan Aztopal, Ferda Ari, Veysel T. Yilmaz, **Engin Ulukaya**. Autophagy Inhibition with Chloroquine Enhances Cytotoxicity Of Palladium (II)-Barbiturate Complex In Prostate Cancer 2nd Congress of Serbian Association for Cancer Research. 2-3 October 2015. Belgrade, SERBIA

26. POSTER AWARD

Merve Erkisa, Şeyma Aydnlik, Buse Cevatemre, Nazlıhan Aztopal, Ferda Ari, Veysel Turan Yilmaz, **Engin Ulukaya**. 27. Ulusal Biyokimya Kongresi. 3-7 November 2015. Antalya

27. POSTER AWARD

Şeyma Aydnlik*, Merve Erkisa*, Buse Cevatemre, Ferda Ari, Veysel T. Yilmaz, **Engin Ulukaya**. Meme Kanseri Kök hücrelerinde Palladyum(II)-Sakkarin/Terpi/Sakkarin kompleks tedavisinin Wnt yolak inhibisyonu ile artan sitotoksik etkisi. 14. İstanbul UNİVERSİTY Onkoloji Enstitüsü Günleri Sempozyumu. 23-24 December 2016, İstanbul

28. POSTER AWARD (3.)

Nazlıhan Aztopal*, Merve Erkisa*, Elif Ertürk, Ferda Ari, **Engin Ulukaya**. Targeting Epigenetic Regulation of Histones with Valproic Acid Leads to Apoptosis in Breast Cancer Stem Cells. 6. Multidisipliner Kanseri Araştırma Kongresi, 27-30 October 2016, Konya, TURKEY

29. ORAL PRESENTATION AWARD

Buse Cevatemre, Merve Erkisa, Nazlıhan Aztopal, Didem Karakaş, Pınar Alper, Chriiida Tsimplouli, Evangelia Sereti, Konstantinos Dimas, Elif İ. İkitimur Armutak, Ebru Gürel Gürevin, Ayca Üvez, Mattia Mori, Simone Berardozzi, Cinzia Ingallina, Bruno Botta, **Engin Ulukaya**. The Plant-Derived Triterpenoid Pristimerin is a Potent Anticancer Agent Due to Its Cytotoxic Activity on Breast Cancer in vitro and in vivo. 6. Multidisipliner Kanseri Araştırma Kongresi, 27-30 October 2016, Konya, TURKEY

30. POSTER AWARD (2.)

Merve Erkisa, Gülay Büyükköroğlu, Behiye Senel, Veysel T. Yilmaz, **Engin Ulukaya**, Ferda Ari. Palladium Incorporated Micelle: A Promising Material for Future Non-Small Cell Lung Cancer. 6th International Congress of Molecular Medicine. 22-25 May 2017, İstanbul UNİVERSİTY Congress and Cultural Center.

Others

- a. MOKAD (Moleküler Kanseri Araştırma Derneği), **President of the Association**
- b. European Association for Cancer Research (EACR) (**Council Member**)
- c. EORTC (European Organisation for Research and Treatment of Cancer) PathoBiology Group (**Member**)
- d. EORTC (European Organisation for Research and Treatment of Cancer) Pharmacology and Molecular Mechanisms Group (**Member**)
- e. COST ACTION CM1106, **Management committee member**
- f. COST ACTION CM1407, **Working group member**

12. Patents

1- Ulusal Patent. TR 2011 00198 B. Düşük dozlarda antikanser aktivite gösteren palladium bileşikleri

2- International patent (United States Patent). Patent no: US 9.839.643 B2 (Dec 12 2017) Bis(2-piridilmetil)amin ve 5,5-dietilbarbitürat içeren yüksek antikanser etkili yeni bir palladyum kompleksi.

3- Armutak EI, Gurel Gurevin E, Kıyan HT, Ulukaya E, Yılmaz VT. An in vivo antiangiogenic effect of a palladium complex. (23.02.2016. Submitted to European Patent Office. EP15203153 (06-15491-A) (at the review phase)

4- Armutak EI, Gurel Gurevin E, Kıyan HT, Ulukaya E, Yılmaz VT. Ulusal Patent TR 2015/15168 BİR PALADYUM KOMPLEKSİNİN IN VIVO ANTİANJİYOGENİK ETKİSİ. (at the review phase)

5- Armutak EI, Gurel Gurevin E, Kıyan HT, Ulukaya E, Yılmaz VT. TR 2016/01308 Bir Paladyum (II) [PdCl(terpi)](sak).2H₂O] Kompleksinin In Vivo Antianjiyogenik Etkisi. (at the review phase)

13. Please fill out the chart below for undergraduate and graduate courses you have given in the last 2 years.

Academic Year	Semester	Course	Weekly Course Hours		Number of Students
			Theoretical	Practical	
	Fall	Cancer biology	2	2	8
		Hot topics in cancer	2	0	8
		Anticancer drug discovery	2	0	8
	Spring	Biology of metastasis	2	0	8
		Cell death detection and cell death modes	2	2	8
		Cancer stem cells	2	2	8
	Fall	Cancer biology	2	2	8
		Hot topics in cancer	2	0	8
		Anticancer drug discovery	2	0	8
	Spring	Biology of metastasis	2	0	8
		Cell death detection and cell death modes	2	2	8
		Cancer stem cells	2	2	8

Note: If given, summer courses should also be added to the chart.